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Abstract
Approximately 1:5000 males have the most common inherited form of severe bleeding, hemophilia A, a
deficiency of functional coagulation factor VIII. Patients with severe hemophilia A suffer from recurrent
bleeding with significant morbidity and mortality with 20-30% of these patients developing antibodies to
infused Factor (F) VIII therapy. One area of on-going research for treatments for these patients is
ectopically expressing FVIII in megakaryocytes and platelets. This FVIII, termed pFVIII, is stored in alpha
granules of platelets and is capable of restoring hemostasis in FVIIInull mice, even in the presence of
circulating inhibitors. pFVIII has been proposed to be used for gene therapy for patients with hemophilia
A, intractable inhibitors, and life-threatening bleeds. However, prior studies by us have shown that high
levels of pFVIII can injure developing megakaryocytes. Combined with the known risk of prolonged
thrombocytopenia following bone marrow transplantation, this may limit its utility of this strategy.
Because of these limitations, we now propose an alternative therapeutic pFVIII strategy of infusing pFVIIIexpressing megakaryocytes or platelets. We envision that such a product would be generated beginning
with induced-pluripotent stem cells (iPSCs). iPSC-derived megakaryocytes, termed iMks, that are modified
to express pFVIII may then be used to improved hemostasis in problematic inhibitor patients with
hemophilia A. As proof-of-principle, we demonstrate that improved hemostasis can be achieved in vitro
and in vivo with human pFVIII-expressing murine platelet. Infusion of such platelets can provide several
days of improved hemostasis in FVIIInull mice. They were effective in the presence of inhibitors, and the
efficacy of pFVIII was enhanced by recombinant factor VIIa. Human pFVIII-expressing iMks also improved
hemostasis in vitro and derived platelets from infused human pFVIII-iMks improved hemostasis in
FVIIInull mice. These studies indicate the potential therapeutic use of recurrent pFVIII-expressing
megakaryocyte or platelet infusions with prolonged hemostatic coverage that may be additive with
present-day bypassing agents in hemophilia A patients with clinically relevant neutralizing inhibitors.
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ABSTRACT
INFUSING FACTOR VIII-EXPRESSING PLATELETS OR MEGAKARYOCYTES AS A NOVEL
THERAPEUTIC STRATEGY FOR HEMOPHILIA A
Randolph B. Lyde Jr.
Mortimer Poncz M.D.
Approximately 1:5000 males have the most common inherited form of severe bleeding,
hemophilia A, a deficiency of functional coagulation factor VIII. Patients with severe hemophilia A
suffer from recurrent bleeding with significant morbidity and mortality with 20-30% of these
patients developing antibodies to infused Factor (F) VIII therapy. One area of on-going research
for treatments for these patients is ectopically expressing FVIII in megakaryocytes and platelets.
This FVIII, termed pFVIII, is stored in alpha granules of platelets and is capable of restoring
hemostasis in FVIII

null

mice, even in the presence of circulating inhibitors. pFVIII has been

proposed to be used for gene therapy for patients with hemophilia A, intractable inhibitors, and
life-threatening bleeds. However, prior studies by us have shown that high levels of pFVIII can
injure developing megakaryocytes. Combined with the known risk of prolonged thrombocytopenia
following bone marrow transplantation, this may limit its utility of this strategy. Because of these
limitations, we now propose an alternative therapeutic pFVIII strategy of infusing pFVIIIexpressing megakaryocytes or platelets. We envision that such a product would be generated
beginning with induced-pluripotent stem cells (iPSCs). iPSC-derived megakaryocytes, termed
iMks, that are modified to express pFVIII may then be used to improved hemostasis in
problematic inhibitor patients with hemophilia A. As proof-of-principle, we demonstrate that
improved hemostasis can be achieved in vitro and in vivo with human pFVIII-expressing murine
platelet. Infusion of such platelets can provide several days of improved hemostasis in FVIII

null

mice. They were effective in the presence of inhibitors, and the efficacy of pFVIII was enhanced
by recombinant factor VIIa. Human pFVIII-expressing iMks also improved hemostasis in vitro and
derived platelets from infused human pFVIII-iMks improved hemostasis in FVIII

null

mice. These

studies indicate the potential therapeutic use of recurrent pFVIII-expressing megakaryocyte or

iv

platelet infusions with prolonged hemostatic coverage that may be additive with present-day
bypassing agents in hemophilia A patients with clinically relevant neutralizing inhibitors.
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Chapter 1 – Introduction
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Hemophilia A

Hemophilia A is a congenital X-linked recessive disease caused by a deficiency
in functional Factor (F) VIII protein that effects 1 in 5000 males1. While the role of FVIII
deficiency in this disorder was discovered in the 20th century, the first accounts of
hemophilia were written in the Talmud, dating back to 2nd century AD2. The Talmud
describes two male babies that died after circumcision and instructs that the third male
baby not be circumcised. By the 20th century, doctors largely believed that the bleeding
seen in hemophilic patients was due to weak vessels3,4. It was not until the early 1900s
that investigators like Sahli and Addis realized that the major hallmark of hemophilia was
a delay in clotting of whole blood5,6. In 1917, Addis showed that small amounts of
“prothrombin” prepared from whole blood could markedly decrease the clotting defect.
However, subsequent studies by Govaerts and Gratia showed that prothrombin could
not be the ultimate culprit whose absence caused hemophilia7. By 1937, Patek and
Taylor, re-examined the small fraction of normal plasma used by Addis and found that
this fraction contained FVIII, which they then called “anti-hemophilic globulin”, that could
markedly improve the clotting defect seen in hemophilic blood8.
Hemophilia A results from loss or reduced function and activity of the FVIII
protein due to mutations in F8 gene1. Mutations in F8 gene that cause hemophilia A
include: point mutations, small and large deletions, splice mutations, and inversions. The
level of residual FVIII activity found in patients’ blood corresponds to the severity of the
disease, which ranges from mild (5-50% of FVIII activity) which makes up 25% of this
patient population, moderate (1-5% of FVIII activity) affecting 10% of patients, to severe
(<1% of FVIII activity) affecting 65% of hemophilia A patients9,10. Nearly half of all severe
2

hemophilia A patients have an intron 22 inversion in their F8 gene11. Severe patients
experience recurrent bleeds in their bodily cavities including their joints, muscles, and
internal organs. These recurrent bleeds can ultimately lead to muscular atrophy and loss
of joint support known as chronic synovitis12. In addition, one of the major complications
of severe hemophilia A is that about 30% of these patients will develop neutralizing
antibodies to infused FVIII therapy, the current mainstay treatment for hemophilia A
patients1,13.

FVIII structure and processing (from gene to plasma)

The F8 gene is located on the distal portion of the long arm of the X
chromosome, maps to position Xq28, and covers 186kb of genomic DNA14. Until
recently, the cellular origin of circulating plasma FVIII within the body was unknown. Cell
isolation studies indicated that liver sinusoid endothelial cells (LSECs) were the main
source of circulating plasma FVIII15-18. While LSECs are the primary source of FVIII
within the body, F8 mRNA is found in many cell types including monocytes and
hepatocytes19. Proper mRNA and protein processing is essential for excretion and
function of the protein1,20,21.
The F8 gene of this large plasma glycoprotein consists of 26 exons that range
from 29 to 3,106 base pairs in length14,21. Fully processed F8 mRNA contains 9 kb of
nucleotides, and in the endoplasmic reticulum (ER), it is translated into a 2,351 amino
acid (267kDa) protein. This single-chain peptide contains 6 domains: 3 A-domains, 2 Cdomains and one large B-domain. Domains A1, A2, and A3 vary little in size with 336,
345, and 335 amino acids respectively and are homologous to ceruloplasmin and factor
3

V (FV) A-domains22,23. C1 and C2 domains are 155 and 152 amino acids respectively
and are homologous to the C domains of FV24,25. The A2 and A3 domain is separated by
the large B-Domain, 980 amino acids, which is the only domain within FVIII that does not
share homology with FV23,26. The B-Domain makes up 40% of FVIII protein. In addition,
FVIII contains 3 acidic regions, a1, a2, and a3. Upon full translation within the ER, the
resulting orientation of full-length FVIII is A1-a1-A2-a2-B-a3-A3-C1-C224,25.
Inside the ER, the FVIII protein is decorated by N-glycosylation at 25 Nglycosylation sites, 19 of which are found on the B-Domain25,27,28. These sites have been
shown to affect overall activity of the functional protein28. During its formation in the ER,
large mannose branched sugars are added to the developing protein. These sugars
work to stabilize and prevent aggregation of newly forming protein domains. To further
facilitate proper folding, the newly formed FVIII binds to chaperone proteins: calnexin
(CNX), calreticulin (CRT), or immonogloblin binding protein (BiP)29-31. FVIII shuttles
between ER proteins: CNX (an ER bound protein) and CRT (a soluble protein in the ER
lumen) until its final glucose is trimmed from its oligosaccharide units that are attach to
FVIII’s asparagine residues21. This CNX/CRT cycle ensures proper folding of the large
protein and helps retain FVIII in the lumen of the ER until this process is complete. If this
process is successful, FVIII detaches from the two lectins and is permitted to leave the
ER and enter the golgi29,31. If FVIII is not folded correctly it is goes back to the CNX/CRT
cycle until it is ultimately released to the golgi or sent to be degraded.
Inside the lumen of the ER, FVIII forms a stable complex with BiP, a key
participant in the unfolded protein response pathway (UPR)32-34. In fact, overexpression
of FVIII in cultured cells results in activation of UPR and increased expression of BiP.
BiP binds to the hydrophobic beta sheet within the A1 domain, which helps retain FVIII
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within the ER lumen. Mutations in this these BiP binding sites have been associated with
increased FVIII secretion35,36.
Properly-folded FVIII binds to a cargo processing complex containing ERGIC-53
(also known as LMAN1) and Multiple Coagulation Factor Deficiency 2 (MCFD2) within
vesicles in order to leave the ER and enter the golgi37. Mutations in ERGIC-53 or
MCFD2 result in a combined FV and FVIII deficiency disorder, which result in FV and
FVIII levels ranging from 5% to 30% of normal38. Upon exiting the ER, FVIII is shuttled to
the golgi apparatus where it is further processed and matured. Inside the golgi, FVIII
undergoes proteolysis and is further matured by keys enzymes (Figure 1.1). However,
before this can take place, FVIII’s N-linked oligosaccharides are modified into branched,
complex structures. In addition, sulfation of tyrosine residues and O-linked glycosylation
of serine and threonine residues within the B-Domain are added21. Tyrosine sulfation is
important for full FVIII activity and interaction with thrombin. In fact, mutations of 6 key
tyrosines to phenylalanine have been shown to decrease the efficacy at which thrombin
can cleave FVIII which results in reduced FVIII activation39.
Before FVIII can be released into the plasma, it undergoes proteolysis by Pairedbasic Amino acid Cleaving Enzyme (PACE/Furin) within the golgi40,41. This intracellular
protease cleaves proteins at arginine-X-X-arginine (R-X-X-R) motifs. Inside the golgi,
PACE cleaves the FVIII B-Domain arginine residues 1313 and 1648 to release the
heavy 200kD (A1-a1-A2-a2-B) and light 80kD (a3-A3-C1-C2) chains of FVIII40,42,43. After
cleavage by PACE, FVIII is excreted from the cell into the plasma in this inactivated
form. This heterodimer is held together by coordinated metal ions. Both copper and
calcium or manganese ions are essential for association of the heavy and light chains as
well as pro-coagulant function44,45. While calcium or manganese do not contribute to the
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two chains maintaining a dimeric structure, they are important for proper configuration
and protein function44,45.
Copper on the other hand, is essential for proper heavy and light chain
dimerization of the inactive and active forms. FVIII copper binding pockets are located
within the A1 and A3. Mutations in the copper-binding site C310F result in severe
hemophilia46,47.
Once inside the blood stream FVIII circulates in its inactivated form at a
concentration of 100-200 ng/ml with ~96% of circulating FVIII bound to its carrier protein
von-Willebrand factor (VWF), synthesized and secreted by endothelial cells48,49. FVIII’s
half-life (~11 hrs) is largely associated with the half-life of VWF50. Patients with severe
VWF disease type 3 have low levels of both vWF and FVIII as the half-life of the free
FVIII is ~2 hours51-53. VWF binds to the C2 and acidic a3 FVIII domains. This VWF–FVIII
interaction works to stabilize FVIII and prevent untoward activation and unintended
thrombosis by preventing FVIII from binding to phospholipids on activated platelets53.
The VWF-FVIII complex also prevents FVIII proteolytic degradation by activated Protein
C (aPC) and activated Factor X (FXa)54-56. Additionally, VWF provides FVIII to sites of
vascular injury by binding activated platelets to vascular sub-endothelium57,58.
The non-covalent VWF-FVIII interaction is disrupted after FVIII is activated by
thrombin (FIIa). FIIa cleaves FVIII at three arginine (Arg) sites: Arg372, Arg740, and
Arg168959. The first cleavage separates the A1 from the A2 domain. The second
separates the A2 from the B domain and final cleavage cuts the acidic a3 domain
releasing FVIII from VWF to form the activated heterotrimer (FVIIIa). After FVIII is
activated and dissociates from vWF, FVIIIa is able to participate in the coagulation
cascade60,61. FVIIIa is short-lived, being unstable, its A2 dissociates rapidly62. In addition,
FIIa, aPC and FXa tightly regulate its activity and inactivation through proteolysis (Figure
6

1.2). Ultimately hepatic elimination of FVIIIa is accomplished by low-density lipoprotein
receptor-related protein (LRP), which binds to the dissociated A3, C2, and A2 domain to
ensure efficient clearance63. These interactions are mediated by heparin sulfate
proteoglycans64.

Coagulation cascade and FVIII co-factor activity

Hemostasis is a delicate and intricate balance of clot formation and lysis,
involving a myriad of key blood proteins that regulate this process. In response to
vascular injury, a series of serine proteases perform proteolytic cleavages to activate
platelets and other blood components to promote blood coagulation and stop excessive
bleeding. Activated thrombin (FIIa) sits at the center of this important physiological
process65. Multiple feed-forward loops ensure that sufficient amounts of FIIa are able to
induce the activation of coagulation factors, leading to the formation of stable plateletfibrin plug at the site of vascular injury. Two pathways (intrinsic and extrinsic) converge
to ensure that sufficient amounts of FIIa are amplified65. FVIII is an important component
of the intrinsic pathway (Figure 1.3).
Upon damage to the vascular wall, tissue factor (TF), a major component of the
subendothelium is exposed to blood circulation. FVIIa binds to TF to activate FX which
with FVa forms the prothrombinase complex (FXa:FVa). This complex is essential for
converting inactive thrombin (FII) into FIIa. FIIa is then able to influence its own
activation by converting factors VIII, V, VII, and XI into their active forms. FIIa also tightly
regulates the inactivation of these proteins through direct proteolysis of cofactors as well
as activation of aPC. FIIa also activates platelets; it is on the surface of these activated
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platelets that FVIIIa binds to FIXa to exert its full co-factor activity. The binding of FVIIIa
to FIXa forms the Xase complex (FVIIIa:FIXa), which converts inactive factor X (FX) to
FXa at a rate of 5 orders of magnitude higher than FIXa alone. This FXa is then able to
bind to more FVa to produce more FIIa as a feed-forward cycle that eventually leads to a
stable platelet-fibrin plug65.

Role of platelets in hemostasis

Platelets have been implicated in a myriad of important bodily functions ranging
from wound repair, angiogenesis, to inflammation, but their main function is in
hemostasis66. Platelets are anucleated cell fragments that are capable of forming
aggregates in response to vascular injury. Platelets can range from 2-5 µm in size and
circulate at a concentration of 150-450K particles per microliter of blood in healthy
individuals67,68.
Platelets are cytoplasmic fractions of megakaryocytes. While megakaryocytes
make up less than 0.1% of nucleated cells in the marrow, they are the largest cells within
the bone marrow niche, growing up to 100 µm in diameter. Some reports indicate that
each megakaryocyte can make up to 104 platelets69,70. The process by which these cells
make platelets has been an area of rigorous study. After maturation, the
megakaryocytes become polyploid through a process known as endomitosis. In addition,
megakaryocytes develops a demarcation membrane system that functions as an
intricate membrane system that allows for proplatelet formation68. These mature
megakaryocytes then extend their proplatelets, long strands of megakaryocyte
cytoplasm, into the sinusoidal vessels of the bone marrow niche where they can shed
mature functioning platelets. The process from megakaryocyte to proplatelet to mature
8

platelet is a complex one that involves many transcription factors and subcellular
players68. Recent studies have shown that megakaryocytes migrate from the marrow to
the lungs intact and shed platelets in that microvascular system71.
Once platelets are released into the circulation, they travel in the blood stream as
non-activated discoid particles that have a half-life of ~10 days72. Endothelial cells act as
a physical barrier, in part, to prevent platelet attachment to the subendothelium. In
addition, the endothelial layer releases factors to keep platelets quiescent. Both
endothelium derived relaxing factor (Nitric Oxide, NO) and prostacyclin (PGI2) released
from endothelial cells work to prevent platelet adhesion, activation, and aggregation73.
Upon vascular disruption, platelets become activated to prevent excessive bleeding.
One key activator of platelets and initiator of clot formation is FIIa, which is
present in high amounts upon exposure of TF and initiation of the coagulation cascade.
FIIa activates platelets by cleaving the tethered ligands on protease-activated receptors
1 (PAR-1) and 4 (PAR-4) on the platelet surface. Cleavage of these G-coupled protein
receptors (GPCRs) activate downstream second messengers that cause conformational
and cytoskeletal changes that allow platelets to better adhere to vWF, collagen, and
other platelet receptors to form a tight plug at the site of vascular injury73.
These cellular signals also increase intracellular Ca2+ concentration within
platelets which allows for the release of their content from platelet granules74,75. Platelets
have three distinct granules within their cytoplasm:

alpha (α) granules, dense (δ)

granules, and lysosomes (λ). These granules contain different proteins and small
molecules either built up during the life span of the megakaryocyte or taken up from the
blood stream. α-granules contain a wide array of proteins both made in the
megakaryocyte or taken up in circulation including vWF, FV, and the platelet-specific CX-C motif chemokine ligand 4 (CXCL4) also known as platelet factor 4 (PF4)76,77. δ9

granules contain smaller molecules like serotonin, divalent metal cations Mg2+ and Ca2+,
and ADP and ATP. In addition, platelets release thromboxane A2 (TXA2), which binds to
GPCRs on activated and surrounding quiescent to further act as a feed-forward
mechanism of activation that further increases intracellular Ca2+.
Key glycoprotein receptors on the platelet surface are imperative for proper
activation and adhesion to other platelets and injured endothelium. Nearly 25,000 copies
of the glycoprotein (GP) Ibα/β-IX (GPIb-IX-V, CD42) receptor are found on the platelet
surface, making it the second most abundant receptor on platelets78,79. GPIb-IX-V binds
to vWF released from endothelial cells to slow platelets from circulation and attach them
to damaged endothelium, and collagen in a process called adhesion79. GPIIb-IIIa (αIIb,
CD41) is essential in platelet-to-platelet binding, mediated by fibrinogen linkages in a
process called aggregation. Both ADP and TXA2 induce a conformational change in
αIIb-β3 that aids in its binding to fibrinogen and thus other platelets to form compact
plugs. About 80,000 copies of the αIIb-β3 receptors decorate the platelet surface,
making it the most abundant platelet receptor80.
Platelets can even be used as a delivery system for potential therapeutics.
Quebec platelet disorder (QPD), a rare autosomal dominant platelet disorder where
urokinase-type plasminogen activator (uPA) is ectopically expressed in platelet αgranules, causes a mild bleeding diathesis in affected individuals81. Our group, created a
QPD transgenic mouse where uPA is ectopically expressed in platelets using the Cxcl4
promoter. Infusing these platelets into WT mice at 5% circulating platelets was able to
prevent full thrombus formation in FeCl3 carotid injury assays82. These experiments
demonstrate that platelets can be used as a delivery system for therapeutic agents in
order to treat disease.
10

FVIII variants

Ever since the successful cloning of the F8 gene in 1984 by several groups14,
researchers have tried to modify the gene and protein to ensure better intracellular
processing, excretion, half-life, and activity of recombinant FVIII. In 1992, full-length
recombinant FVIII was approved and came onto market for treatment of patients. The
full function of the FVIII B-domain is not currently known, however it has been
speculated that it could play a role in FVIII synthesis, quality control, secretion, plasma
activation, platelet binding, and even clearance28. In the mid 1990’s, scientists
discovered they could delete the B-domain in FVIII to ensure more efficient cloning of
the gene while sparing functionality and half-life of the protein83,84. To improve production
and yield of the protein, scientists and companies have removed the B-domain. By 2000,
B-domainless FVIII was available for clinical use85,86.
Our studies utilize variations of the B-domain deleted FVIII mentioned above.
The first is a human B-domainless FVIII (hBDFVIII) that contains a residual 14 amino
acid peptide from the B-domain that links heavy and the light chain and allows for proper
processing by PACE/Furin enzyme. This previously described modification has minimal
effect on circulation half-life and activity of FVIII84. The other FVIII variants utilized in our
studies have a mutation in the PACE/Furin cleavage site within this residual 14-amino
acid domain that prevents PACE/Furin from cleaving the single chain protein into the
heavy and light chain, hBDFVIIIR1645H (RH), and FVIIIΔ 42. hBDFVIIIRH has a mutation in the
furin cleavage site while FVIIIΔ has a 4-amino acid deletion from amino acids 1645-1648
of the entire PACE/Furin recognition sequence. These mutations cause the resulting
11

FVIII to be predominately expressed as a single chain which has been shown to cause a
delay in A2 domain dissociation and therefore increased biological activity42,87.
Previous studies by Dr. Sabatino showed that canine (c) BDFVIII was secreted
primarily as a single chain when expressed in baby hamster kidney (BHK) cells. In
addition, this cBDFVIII was more stable and had higher biological activity. Interrogation
of its amino acid sequence revealed one key difference in its PACE/Furin cleavage site
when compared to hBDFVIII42,88. cBDFVIII contained a histidine at amino acid 1645
(HHQR) instead of an arginine like in humans (RHQR)88. Further studies of cBDFVIII
indicated that it was this amino acid difference that allowed for suboptimal cleavage by
PACE/Furin and the excretion of this protein in its single chain form resulting in higher
biological activity88. Taking these cues from cBDFVIII Sabatino and colleges developed
hBDFVIIIRH.

FVIII inhibitors
One major complication of FVIII therapy in severe hemophilia A patients is the
development of alloimmune neutralizing antibodies (inhibitors) to FVIII. Inhibitors are a
mixed composition of immunoglobulin G (IgG) subtypes 1-4 with IgG4 being the most
prevalent. These inhibitors are broadly classified into two types based on effects on
FVIII. Type 1 completely inhibits FVIII activity through second-order kinetics. Type 2
partially inhibits FVIII activity. Type 1 inhibitors are more prevalent in patients with
severe hemophilia, while type 2 is more common in mild and acquired hemophiliacs89.
Inhibitors are detected and quantified via Bethesda assay or the Nijmegen-modified
Bethesda assay90. These assays only detect inhibitors that reduce FVIII activity. Each
assay uses serial dilutions of inhibitor plasma incubated with normal plasma. A Bethesda
12

unit (BU) is the amount of inhibitor to reduce FVIII activity level by 50%, this
measurement is on log scale. Patients with a BU titer of 5 or below are considered low
titer, a BU of greater than 5 is considered high-titer91.
Twenty-Thirty percent of patients with severe hemophilia A develop inhibitors.
The risk of developing inhibitors is highest 10-15 days after first exposure to FVIII13.
Specific genetic mutations are correlated to higher risk of inhibitor formation. Patients
with large FVIII deletions have the highest rate of inhibitor formation. In contrast, patients
who have mutations that result in loss of function, but where their FVIII retains the
majority of its structure have lower risk of inhibitor formation. Race and ethnicity can also
play a role in inhibitor formation. African-Americans and Hispanics have higher rates of
developing an inhibitor than other ethnic groups92,93.
Many patients that develop inhibitors respond to immune tolerance induction
(ITI) with FVIII.

ITI is accomplished through high dose (>200 IU/kg/day in some

protocols) infusions of FVIII twice a day, once a day, or every other day depending on
the

protocol94,95.

Newer

ITI

protocols

have

included

immunomodulating/immunosuppressive therapies like cyclophosphamide in combination
with high-dose FVIII96. However, a significant number of patients do not respond and
have persistent high-titer intractable inhibitors with recurrent, sometime life-threatening
bleeds95. Bypassing agents, such as activated prothrombin complex concentrate
(FIEBA),

recombinant

FVIIa,

or

potentially

emicizumab

(ACE910),

which

heterodimerizes FIX and FX are not always effective, have short half-lives (FIEBA and
FVIIa)97, or have a prothrombotic risk (all three)97,98.

Induced pluripotent stem cells (iPSCs) and hematopoietic applications
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We utilized iPSCs to derive megakaryocytes and platelets. iPSCs were obtained
by reprograming somatic cells either from peripheral blood of patients or healthy donors
and transducing them with a set of stem cell transcription factors. In 2006, Takahashi
and Yamanaka, successfully reprogrammed adult mouse fibroblasts into iPSCs through
viral transduction with transcription factors Oct-4, Sox-2, Klf4 and c-Myc. The
subsequent cells had similar morphology and subcellular characteristics as embryonic
stem (ES) cells99,100.
One important characteristic that these IPSCs share with ES cells is that they are
pluripotent, being able to give rise to a myriad of cells types. When subcutaneously
injected into mice, iPSCs form teratomas. These tumors developed cells from all three
germ layers: ectoderm, mesoderm and endoderm99. This quality of iPSCs meant they
had the potential to be differentiated into many different cell types. In our case, we
showed that these cells could be differentiated into the hematopoietic linage. Previous
studies by our group showed that iPSCs could also be gene manipulated to carry
transgenes for enhanced green fluorescent protein (eGFP), Friend leukemia integration
1 transcription factor (FLI-1), and αIIb-β3 under the control of the murine Gp1ba
promoter.

Upon differentiation into megakaryocytes and platelets, the transgene of

interest was expressed at high levels. Differentiation into other linages did not lead to
expression of the protein101,102.
In addition, these cells are able to self-renew indefinitely99. This allows
researchers to have a near-unlimited supply of starting material to study complex and
rare diseases. Even more important in the case of hemophilia A therapy, one would only
need to remove and reprogram cells once and have a limitless supply of transfusable
material for the patient at will. Additionally, iPSCs have the therapeutic advantage of
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potentially being derived from patients’ own cells. This could ultimately limit the risk of
graft-vs.-host disease and eliminate potential immune rejection.

Platelet gene therapy for hemophilia A

Gene therapy is the transduction of normal or modified genes into a patient’s
cells to treat a disease. Ideal gene therapy for patients with hemophilia A would involve
long-term correction of plasma factor (F) VIII levels by establishing FVIII expression in
tissues that physiologically express this protein103,104. Progress has been made to this
end; however, if the patient has a pre-existing inhibitor, plasma correction is not likely to
be effective with the following caveat: if plasma FVIII’s continued expression suppresses
inhibitor formation or if the immune suppression used in some forms of gene therapy
(e.g., bone marrow engraftment) is successful in eliminating the inhibitor, then such gene
therapies may be useful105,106.
Previous studies by our laboratory and others have demonstrated that ectopically
expressing FVIII within platelets (pFVIII) could be a viable alternative to plasma
correction for effective therapy in patients with significant hemophilia A and intractable
inhibitors107-109. Through several transgenic mouse models of expressing pFVIII, these
groups were able to demonstrate that this approach differs from plasma correction:
pFVIII expressed in platelet α-granules and is released only upon platelet activation and
degranulation110. Thus the pFVIII would be localized to sites of bleeding, potentially
making it more efficacious at lower doses108,109. Storing FVIII within platelets would also
extend it’s circulatory half-life to that of the half-life of platelets, ~10 days in humans111.
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Finally, the sequestered pFVIII may be protected from inhibitors until released within the
clot and be especially effective in patients with inhibitors.
Patients can receive pFVIII in two ways. The first, and most direct approach
being pursued by my group and others, is long-term expression through permanent,
genetic modification of hematopoietic stem cells (HSCs) so that FVIII is specifically
turned on in megakaryocytes and platelets. HSCs have the capability of differentiating
into all blood lineages, most importantly megakaryocytes and platelets112. In addition,
HSCs have the ability to self-renew and can continue to make megakaryocytes
expressing pFVIII for life. This long-term approach would be accomplished through
autologous bone marrow transplant (BMT). The second approach is accomplished
through infusions of modified platelets derived from HSCs. These HSCs can be obtained
from a myriad of sources including peripheral blood mobilized adult bone marrow113,
from umbilical cord blood, from fat cells, or from iPSCs114. All can be genetically modified
to express pFVIII upon differentiation into megakaryocytes, but only cells like cord blood
expanded with valproic acid115, fat cells116,117 and iPSCs can be markedly expanded to
have practical utility.
Previous studies have used tissue-specific promoters to target FVIII transgene
expression to megakaryocytes and platelets. This may have the advantage of reducing
potential immune response to FVIII leaking out of other cell lines at low levels,
preventing the further development of inhibitors. These promoters include but are not
limited to GPIBA108, ITGA2B118, CXCL4119, GPV120, and GPVI121. Each promoter is active
during megakaryopoiesis and is fairly well expressed.
Previous studies from our laboratory have demonstrated the therapeutic efficacy
of pFVIII. Using the murine platelet specific-promoter Gp1ba, hBDFVIII was expressed
solely in platelets and megakaryocytes of transgenic mice on a FVIIInull background (Line
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h38)108. We verified that Line h38 mice expressed a FVIII equivalent of 3% normal
plasma activity and 9% antigen level (as human FVIII has ~30% specific activity in
mouse plasma)108. This pFVIII level of expression was able to correct the hemophilia A
phenotype in FVIIInull mice in several hemostatic challenges. In a mouse BMT study, we
used the platelet-specific murine Cxcl4 promoter to express hBDFVIIIRH in platelets of
FVIIInull mice109. When comparing these mice to mice that expressed hBDFVIII in their
platelets, hBDFVIIIRH showed greater hemostatic efficacy in both the FeCl3 carotid and
cremaster laser injury models, consistent with the known greater biological activity of
hBDFVIIIRH 42,109.
pFVIII also shows efficacy in the presence of FVIII inhibitors. We previously
showed that pFVIII in Line h38 mice was efficacious in FeCl3 injury after infusion of a 1:5
mixture of two FVIII inhibitors, ESH8 and GMA-8021107. In another study, Dr. Shi and
group demonstrated that transgenic mice expressing pFVIII was efficacious in the
presence of high-titer inhibitors using a tail-clip exsanguination model118, but we have
argued that this model may be too sensitive to low levels of released pFVIII under nonphysiologic (almost static) setting.
To date, one study has demonstrated pFVIII efficacy in a canine model of
hemophilia A. While this study showed that long-term canine pFVIII expression (5-9
mU/108 platelets) could be achieved, it failed to test its efficacy in the setting of a
hemostatic challenge model. Furthermore, this pFVIII was not tested in an inhibitor
setting. In addition, only three dogs were studied, each having limited FVIII levels within
their platelets122.

Limitations of pFVIII
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While pFVIII is a potential therapy for Hemophilia A patients with inhibitors, there
are several limitations of expressing pFVIII by BMT gene therapy. Currently, assessing
the degree of pFVIII protection in the presence and absence of inhibitors has been
difficult in animal models. No model showing bleeds comparable to those affecting
patients is available. Hemostatic assays such as the murine tail-clip exsanguination
assay tend to be especially sensitive to low levels of pFVIII. Released pFVIII from αgranules is not temporally or spatially available as plasma FVIII, which may explain its
efficacy in the presence of inhibitors and its greater efficacy in some hemostatic models,
but not in others. This temporal difference is likely the cause of potential emboli in pFVIII
cremaster models of thrombosis our group has previously reported. To expose a patient
to BMT gene therapy with no assurance of efficacy with and without circulating inhibitors
in a hemophilia A patient with significant bleeds in targets including joint, retroperitoneal,
and intracranial would be risky.
Additionally, achieving high-levels of pFVIII per platelet has been problematic
with one report by Dr. Shi’s group describing an ~0.2 U/ml antigen correction in mice123.
Whether the mice were accompanied with thrombocytopenia is not clear, as platelet
counts in those animals and response of these mice to platelet production challenges
were not reported123. Ectopically expressed FVIII can cause injury to the expressing cell
due to poor intracellular processing of the FVIII. We showed this to occur in developing
Mks, especially expressing canine FVIII and less so for hBDFVIII109. Achieving high
levels of pFVIII expression is a desired goal, but may result in injured developing Mks
and worsen post-BMT thrombocytopenia. A combination of thrombocytopenia and FVIII
deficiency with inhibitors may be clinically challenging. Therefore, pFVIII BMT therapy
has three theoretical limitations: 1) The post-BMT thrombocytopenia may be worsened
by pFVIII, 2) Efficacy of pFVIII in target organs of patients with hemophilia A has not
18

been established, and 3) whether pFVIII may be effective in these target organs in the
presence of inhibitors has yet to be tested in spite of the existence of a FVIIInull dog
model of pFVIII.

Motivation for studies
While pFVIII has many advantages it also has its limitations, particularly in the
setting of BMT. The purpose of these studies is to try to address some of the limitations
of pFVIII in the setting of BMT, persistent inhibitors, and life threating hemophilia A
disease, offering an alternative therapeutic approach for pFVIII therapy in hemophilia A.
To overcome the aforementioned limitations, I propose an alternative strategy for pFVIII
therapy: expressing pFVIII in in vitro-grown megakaryocytes (Mks) and using the pFVIIIMks to generate platelets for acute or for prophylactic care in severe hemophilia A
patients with uncontrollable inhibitor titer and a history of life-threatening disease. Such a
strategy may be able to be given through weekly prophylactic infusions and be used in
conjunction with acute treatment with bypassing agents for bleeds. Efficacy in a
particular patient may also be an indication that that patient may be a good candidate for
undergoing pFVIII BMT, with the potential of using pFVIII platelet infusion therapeutically
during the immediate post-BMT period.

Summary
pFVIII as a potential therapy for Hemophilia A patients with intractable inhibitors
has been an ongoing area of study. While strides have been made to bring this potential
therapy to clinic, this approach in the setting of BMT is potentially problematic to a
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subset of severe hemophilia A patients with high-titer inhibitors. This thesis seeks to
address these limitations with an alternative approach of pFVIII therapy. By utilizing
mouse Line h38 platelets that express hBDFVIII and hBDFVIII-containing human iPSCderived megakaryocytes (iMks), I explored the therapeutic benefit, both in vitro in a
rotational thromboelastography assay (ROTEM) and in vivo in FVIIInull mice. I
hypothesize that the Line h38 platelets infused into FVIIInull mice would simulate
outcomes expected in patients treated in a similar fashion with modified human platelets
made in vitro. Our group has shown that infused iMks release platelets in vivo with
similar biology as endogenous platelets and I hypothesize that pFVIII-iMks will give rise
to platelets in vivo and these functionally derived platelets will mitigate the FVIIInull
phenotype in mice. I show that the hemostatic effects with these approaches persist in
vivo for several days. This therapeutic strategy is also effective in the presence of
inhibitors, and can be additive with rFVIIa. The potential uses and limitations of this
infused pFVIII approach are also discussed. Chapter 2 summarizes the potential use of
infusions of FVIII containing platelets from our highest expressing hBDFVIII transgenic
Line h38 mice to improve hemostasis in the presence and absence of inhibitors. In
addition the ability of these platelets to have a combinatorial effect with rFVIIa bypassing
agent is also explored here. Chapter 3 outlines the generation and characterization of
iPSCs, viral transduction, and FVIII expressing iPS megakaryocytes iMks. This chapter
also details in vitro and in vivo effects of FVIII containing iMks on clot formation and
thrombosis. Chapter 4 describes other studies utilizing human IgG localization in
megakaryocytes to better understand how pFVIII achieves its protection from inhibitors
as well as lessons learned from adenovirus-associated site 1 (AAVS1) to express pFVIII
in iPSCs. Chapter 5 will conclude this thesis with clinical implications and future
directions of the outlined studies.
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Figures

Figure 1.1: Interaction with ER proteins help to mature FVIII (adopted from Randal
Kaufman21)
Developing FVIII binds to critical ER chaperones: BiP, CNX, and CRT that help ensure
the protein is properly folded. After being fully translated FVIII binds to CXN and RT that
help fold and prune sugars on glycoproteins. FVIII stays within this CNX/CRT complex
until folded into the correct configuration. If FVIII is properly folded, it exits the ER. Upon
leaving the ER, properly folded FVIII binds to ERGIC-53/MCFD2 and trafficked to the
Golgi for further processing. If FVIII is not properly folded, it exits the CNX/CRT complex
and bids to BiP. FVIII binding to BiP marks it for Endoplasmic-reticulum-associated
protein degradation (ERAD) and FVIII is degraded.
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R1645H, Δ

Figure 1.2: FVIII protein structure, activation, and inactivation (adopted from Steve
W. Pipe28).
From top, Red line in full length FVIII indicates R1634H and Δ mutation in order to create
variants. Full length FVIII is processed within LSEC cells and then secreted into the
blood stream as heterodimer held together by a divalent metal ion. Thrombin then
cleaves the B-domain from heavy chain of FVIII and the a3 acidic domain allowing VWF
to dissociate. Upon further thrombin processing FVIII becomes a heterotrimer and the
activated FVIIIa, at which point it can exhibit its co-factor activity. Inactivation occurs
quickly through dissociation of A2 domain and further proteolysis by thrombin and aPC.
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Figure 1.3: FVIII’s role in hemostasis and clot formation.
FVIIIa’s role in the intrinsic pathway of the coagulation cascade. Exposure of tissue
factor (TF) at the site of vascular injury binds to FVIIa and activates FX. Activated FVIII
works as a co-factor with FIXa to convert FX to FXa. Red box indicates FVIIIa:FIXa Xase
complex. These two pathways ultimately increase the level of FIIa, which cleaves
fibrinogen to fibrin to form. This fibrin is then able to bind to platelets and form a
cohesive platelet plug at the site of vascular injury.
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Chapter 2 – In Vitro and In Vivo Hemostatic Therapeutic Efficacy of FVIIIContaining Mouse Platelets
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Abstract
pFVIII is able to correct the bleeding phenotype seen in FVIIInull transgenic
animals, however, to date this has been accomplished largely by bone marrow
transplant (BMT) which can be problematic in patients with hemophilia A and intractable
inhibitors. We tested an alternative pFVIII-approach using platelets containing hBDFVIII
at a fairly high level to examine its potential therapeutic value. We envision that our
studies will show that infused pFVIII platelets can provide hemostatic efficacy for a
relatively prolonged period of time and can be used additively with a bypassing agent
and can do so in spite of the presence of an inhibitor. In this chapter, I describe the in
vitro and in vivo efficacy of infusing FVIII containing platelets as a therapy for Hemophilia
A, their therapeutic efficacy in the presence of FVIIa, and the efficacy of pFVIII in the
presence of inhibitors with and without FVIIa. First, I describe the transgenic mice used
in these studies, FVIIInull and our murine transgenic Line h38 expressing hBDFVIII in
their platelets on FVIIInull background. Line h38 is the highest expressing hBDFVIII
transgneic line available to us. It has been breed onto the FVIIInull background. Efficacy
of pFVIII line h38 platelets were studied in an in vitro ROTEM assay with and without a
bypass agent. The ability of infused pFVIII platelet infusion to abrogate the FVIIInull
phenotype seen in in vivo FeCl3 carotid assay, and tail-vain exsanguination assay were
done and the half-life of the observed hemostatic improvement was followed. Finally, the
effects of combined efficacy of FVIIa and infused pFVIII in FeCl3 assay in the presence
and absence of FVIII inhibitors was examined. These studies showed that pFVIII infused
platelets can provide a relative prolonged therapeutic benefit that was effective in the
presence of inhibitors and that was enhanced by inclusion of a bypass agent.
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Introduction
Genetically modified animals or transgenic organisms are a powerful research
tool utilized by many laboratories. Dr. Ralph Brinster in collaboration with Dr. Richarad
Palmiter at the University of Pennsylvania was one of the first researchers to
successfully create a transgenic mouse that was capable of passing its genetically
altered genes to its offspring124,125. While Brinster and Palmiter first used this technology
to express oncogenes in mice, their techniques and ideas proved to be translatable to an
array of genes that allow researchers to mimic clinical disease states and to study
potential therapeutic interventions.
To this end, our laboratory has utilized a FVIIInull mouse model of hemophilia A,
first created and described by Dr. Kazazian, that exhibits the prolonged bleeding time
seen in hemophilia A patients126,127. These mice have a disruption in exon 16 of their
FVIII gene that results in a truncated dysfunctional form of the FVIII protein. This
mutation ultimately causes a severe form of the disease with <1% FVIII activity126. While
these mice have no residual FVIII activity, they do not develop spontaneous bleeds into
their joints as humans do. However, following a number of hemostatic challenges, these
mice can bleed to death. For example, tail transection of these animals causes them to
expire a few hours post clipping128.
One major hallmark of severe hemophilia A in human is the occurrence of
significant arthropathy of the synovial cavities of the large joints129,130. For patients that
lacked regular FVIII replacement therapy, by age 25 years over 85% of these patients
have major morphology changes in key joints129. An injury model of chronic synovitis has
been developed for these mice where mechanical trauma is induced in these joints131.
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These models have been used to test the effect of bypassing agents in these animals;
however, there are several limitations with this model the first being these bleeds are not
spontaneous as in humans132. The second is that these models do not mimic weight on
these joints as seen in humans133. Like humans, however, these mice develop
antibodies to infused FVIII. Their immune response to infused FVIII is very similar to that
in severe hemophilia A patients that develop inhibitors and has been extensively studied
and used to develop potential therapeutic134.
Our laboratory has utilized these mice to test the efficacy of a platelet delivery
system for FVIII. In 2003, Dr. Yaravoi developed transgenic mice lines that expressed
hBDFVIII solely in their megakaryocyte and platelets, driven off of the murine Gp1ba
promoter. The highest expressing transgenic line, Line h38, had an antigenic FVIII level
of 9% and an activity level of 3% determined by ELISA and Coatest assays,
respectively108. This level of expression is able to almost completely rescue the
hemophilia A phenotype in a FeCl3 carotid artery model. These mice achieved occlusion
similar to wild-type mice and to FVIIInull mice infused with a 50% soluble hBDFVIII
correction dose. Furthermore, these studies indicated that in all the transgenic lines,
FVIII was in the platelet α-granules with none detected circulating in the plasma after
they were crossed onto a FVIIInull background. The pFVIII was shown to colocalize with
vWF, presumably in α-granules, and could be released upon platelet activation108.
The efficacy of these platelets was directly compared to infused recombinant
hFVIII in the presence of an inhibitor mixture consisting of ESH8 and GMA-8021.
Gewirtz et al. showed that Line h38 mice were able to protect against FVIII inhibitor
inactivation better than plasma FVIII. The efficacy seen in the FeCl3 was modest, 6-7
fold improvement in BU per mL compared to hFVIII infusion107. These results were
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slightly different than those seen with the pFVIII mouse developed by Dr. Shi’s group.
Using the tail-vein exsanguination model, they showed that pFVIII was efficacious in the
presence of high-titer inhibitor and protective top >20 BUs118.
Obtaining high levels of pFVIII in transgenic animal models as well as cell lines
has been challenging. One reason is that FVIII is toxic to the expressing ectopic cell and
expressing it at high levels can lead to ER stress and apoptosis135. We showed that
expressing canine FVIII injured megakaryocytes, and that hBDFVIII was also
deleterious109. Canine pFVIII expression in mice through lentiviral BMT showed that
canine FVIII could inhibit platelet production from donor-derived megakaryocytes. To
date, Dr. Shi has developed a transgenic mouse that expresses ~0.2 U/ml antigen
correction, roughly twice that seen in Line h38123. We utilized our Line h38 mice in our
studies because it is the transgenic line with the highest level of pFVIII that is available
to us and has been well characterized, including measurements of the platelet count and
response to various hemostatic challenges108,110.

Human FVIII inhibitors
About twenty-thirty percent of patients with severe hemophilia A that have
received recombinant FVIII therapy will develop inhibitors to the infused therapy. Type 1
inhibitors inactivate FVIII through potentially binding to the A2 and A3 domains of FVIII89.
These sites are close to the bindings sites for FIXa. Another main epitope of FVIII
inhibitors is the C2 domain that binds to the surface of platelets. After inhibitors bind and
inactivate FVIII, the FVIII is quickly cleared. Some inhibitors even bind to FVIIIassociated proteins such as: FIXa, FXa, and VWF. The inhibitor studies outlined in this
chapter are a mix of two inhibitors commonly used in inhibitor studies and that are wellcharacterized, ESH8 and GMA-8021. ESH8 is a mouse monoclonal antibody that binds
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to the human FVIII C2 domain in the presence of VWF136,137. GMA-8021 is a mouse
monoclonal antibody also originally known as R8B12138 binds to the C2 domain of
FVIII139,140. We previously showed that a 1:5 (µg:µg) could fully inhibit plasma FVIII when
infused into a FVIIInull recipient mouse at 1ug/gram107.

Bypassing agents
Current treatment for hemophilia A patients with inhibitors is ITI with high levels
of infused FVIII with or without immunosuppression therapy95. Where high-titer inhibitors
persist, bleeds are treated with bypassing agents. Currently there are two FVIII
bypassing agents that are clinically used to treat Hemophilia A patients with inhibitors,
rFVIIa and activated prothrombin complex concentrates (aPCCs), notably FEIBA. A
potential third therapy is emicizumab (ACE910), which heterodimerizes FIX and FX,
which is currently undergoing clinical trials.
The first two bypassing agents are used for either prophylactic treatment or for
acute events. aPCC is produced from pooled plasma that contains factors all of the
vitamin K-dependent factors: VII, II, IX, and X. rFVIIa is a purified recombinant protein
that has reported efficacy in patients with inhibitors with acute bleeds141,142. rFVIIa doses
for inhibitor patients ranges from 35-90 µg/kg. Its expense and its short half-life of 2-3
hours are its most challenging limitations143-145. aPPCs also have reported efficacy in
patients with inhibitors. rFVIIa and aPPC has a reported efficacy rate of 85% and 80% in
inhibitor patients respectively. While both have significantly improved quality of life for
hemophilia A patients with inhibitors, these bypassing agents are not as effective as
FVIII at treating acute bleeds and their short half-lives limits their prophylaxis use141,142.
To note, ACE910 is currently in phase three clinical trials and has shown promise
as a bypassing agent146. This humanized bispecific antibody mimics activated FVIIIa
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binding FIX and FX. ACE910 has good bioavailability after subcutaneous injection and
has a half-life of up to 5 weeks147. A 12-week study showed 72% of patients enrolled in
the study with inhibitors had no bleeding events while on the therapy. Dose regimens
included 0.3, 1.0, or 3.0 mg/kg once a week146. Unfortunately, the success was marred
due to a patient’s death post conclusion of the initial study. While on ACE910, this
patient being treated for a rectal hemorrhage, developed signs of thrombotic
microangiopathy and died98. Whether the occurrence of thrombotic microangiopathy on
this drug will be a common complication in a significant number of patients needs further
study.

Materials and Methods

Mice lines
FVIIInull mice with exon 16 disruption in F8 gene126,127, the murine transgenic Line
h38 expressing hBDFVIII in their platelets108, and the transgenic hαIIb-expressing
line148,149 were previously described. Line h38 mice are on the FVIIInull background, but
are designated simply as Line h38. All mice have been previously backcrossed onto a
C57Bl6 background for >10 generations. In all studies, 6-10 weeks of age littermate
mice of either sex were studied.

Isolation of whole blood and platelets
Whole blood of FVIIInull, Line h38, and hαIIb-expressing mice were collected from
the inferior vena cava in 3.8% sodium citrate as described150,151. Mice were anesthetized
using pentobarbital (80 mg/kg, Akorn Pharmceuticals) and vena cava exposed. Up to
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1ml of whole blood was then collected into 1 ml BD syringes using a 23-gauge needle
(precision glide, BD, New Jersey). 3.8% Sodium citrate was added to the whole blood to
obtain 10% of total volume. Whole blood was used directly in ROTEM studies or for in
vivo infusion studies after isolation of platelets using differential centrifugation as
previously described. To isolate platelets, 1 µl of PGE-1 was added to whole blood to
prevent platelet activation. Whole blood was then centrifuged for 10 minutes at 860 RPM
to first isolate platelet rich plasma (PRP). The PRP was then spun at 3000 RPM for 8
minutes, and the resulting platelet pellet was washed twice and then re-suspended in
PBS or platelet re-suspension solution. In some studies, supernatant from PRP was
tested for the presence of FVIII as previously described108,152 (data not shown). Total
blood and platelet counts were determined using a HemaVet counter (Triad Associates)
prior to study. Whole blood and platelet suspensions were used within 1 hour for both in
vitro and in vivo infusion studies. In some studies, Line h38 whole blood was mixed with
that of FVIIInull mice to obtain decreased percentages of Line h38 platelets.

ROTEM studies for pFVIII
Whole murine blood was recalcified to 10 mM with 0.2 M CaCl2, and then 110 µl
of whole blood was transferred to 37°C ROTEM minicups (Werfern) for assessment via
ROTEM

thromboelastometry

using

an

INTEM-based

assay,

as

previously

described153,154. INTEM reagent (Werfern), an intrinsic pathway activator of kaolin155, was
used to activate mouse whole blood. In some studies, supplemental rFVIIa (1-50 nM,
final concentration, NovoNordisk) was added to FVIIInull whole blood ROTEM cups. In
other studies, iMks expressing either hBDFVIII or the hBDFVIIIRH variant, eGFP, or no
added protein non-transduced control (NTC) were added to FVIIInull whole blood in
ROTEM minicups. Care was taken to insure that no more than 10 µl of cell suspension
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was added to whole blood. In other studies, human full-length rFVIII (0.01-1.0 ng/ml final
concentration, Advate, Shire) was added to FVIIInull whole blood as a positive control.
The thromboelastometry assay was carried out for up to 30 minutes, and data were
collected and analyzed via ROTEM software (Werfern). Typical ROTEM readout and
parameter collected for these experiments are illustrated in Figure 2.1.

rFVIIa
rFVIIa utilized in these studies in vitro and in vivo studies was obtained from
NovoNordisk (1mg doses). 1.1 ml histidine diluent, supplied, was used to reconstitute
lyophilized powder. Protein was used immediately for infusion studies or aliquoted and
stored at -80°C.

Mouse platelet half-life studies
To define platelet half-life and total percentage of infused circulating platelets
post infusion, 4x108 hαIIb-expressing or calcein AM-loaded platelets were infused into
FVIIInull mice and analyzed over 72 hours via flow cytometery. Platelets were infused via
the tail-vein and blood collected from the retro-orbital sinus at various time points. Blood
was collected using Microhematocrit Capillary Tubes (Fisherbrand) into minicapillary
blood collection tubes prepared with EDTA DI potassium salt (RAM Scientific Inc.). 1 µl
of blood was added to 100 µl antibody solution containing anti-CD41a-allophycocyanin
(APC),

and

anti-CD42b-phycoerythrin

(PE)

(both

BD

Biosciences)

antibodies.

Antibody/blood samples were allowed to incubate for 20 minutes at room temperature.
400 µl of phosphate buffered saline (PBS,Gibco) was added to each sample after
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incubation, and the samples were analyzed via flow cytometry using a BD FACSCanto II
(BD Biosciences) and further analyzed using FlowJo software.

Tail-clip exsanguination assay
The tail-clip exsanguination assay were performed in FVIIInull mice after they had
received up to 4x108 Line h38 or FVIIInull control platelets in 100 µl in PBS, 0.5-72 hours
prior to the injury. Controls also included FVIIInull mice that received 100 µl of PBS. In
some studies, FVIIInull mice were infused with 0.25, 1 and 4 mg/kg rFVIIa retro-orbitally,
up to 2 hours prior to injury. After these infusions, mice tails were resected to 2mm in
diameter to allow for significant bleeding118. Mice were allowed to bleed overnight and
then checked up to 16 hours post tail resection. The primary endpoint was the number of
mice surviving over night.

FeCl3 carotid injury assay
The FeCl3-induced carotid artery injury assay in FVIIInull mice was previously
described by us and shown to correlate to the amount of recombinant hFVIII
infused108,109,152. Mice were transfused with either 2-4x108 Line h38 or FVIIInull platelets
0.5-72 hours after being anesthetized using pentobarbital (80 mg/kg). The right carotid
artery was then isolated and exposed to a 20% (W/V) FeCl3-saturated 1 X 2 mm
Whatman 1 filter paper for 3 minutes. Upon removal of the FeCl3-saturated paper, the
open surgical site was filled with PBS. Blood flow was then measured using a Doppler
flow probe (Model 0.5VB, Transonic Systems). Total flow was recorded for 30 minutes,
and the volume of blood flow over that time-frame was the primary endpoint.
In some FeCl3 carotid artery injury studies, 0.1-2.0 µg of inhibitors per gram of
mice in a total of 50 µl of water (see next paragraph) were infused via the jugular vein of
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mice prior to the FeCl3 carotid injury assay. In other injury studies, rFVIIa at a
concentration of 1-4 mg/kg was infused immediately prior to the FeCl3 carotid injury
assay. In other studies, rFVIIa was infused via the jugular vein into FVIIInull mice at a
concentration of 0.25-4.0 µg/kg concurrent with Line h38 platelet infusion and 0.1-2.0 µg
inhibitor mixture.

FVIII inhibitors
For several studies, FVIII inhibitors were infused. Based on a prior study from our
group showing optimal inhibition of plasma FVIII and pFVIII biology, a cocktail of two
FVIII inhibitors consisting of 1 µg of ESH8 (BioMedica Diagnostics) plus 5 µg of GMA8021 (Green Mountain Antibodies) was used107. GMA-8021 is an IgG2a anti-human FVIII
antibody that has specificity to the A2 domain138. ESH8 is a potent inhibitor that binds to
the FVIII C2 domain in the presence of VWF and is also an IgG2a isotype137,156. 0.1-2.0
µg of inhibitors mixture per gram of mice in a total of 50 µl of water were infused into the
mouse via the jugular vein.

Animal study approval
All studies were carried out with the approval of the Children’s Hospital of
Philadelphia’s Institutional Animal Care and Use Committee.

Statistical analysis
Statistical differences between arms were determined using a two-sided
Student’s t-test or analysis of variance (ANOVA) with Bonferroni, Dunnett’s or Tukey’s
corrections of multiple comparisons, when appropriate. PRISM 7.0 (Graphpad) was used
to calculate statistical significance. P-Values ≤0.05 were considered significant.
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Results
ROTEM studies with recombinant full-length hFVIII
To evaluate the hemostatic efficacy of pFVIII, we first determined the hemostatic
efficacy of hFVIII added at varying concentrations of 0.01, 0.1, and 1.0 ng/ml in FVIIInull
mouse whole blood on ROTEM analysis (Figure 2.2). ROTEM is particularly sensitive to
deficiencies in whole blood and plasma. Using this method allowed us to notice small
changes in FVIII that may be efficacious in FVIIInull whole blood. Each concentration of
soluble FVIII showed some level of clot formation. Results were seen in a dosedependent manner with 0.01 displaying the least amount of clot formation.

In vitro studies using Line h38 platelets and rFVIIa
ROTEM analysis was then used for in vitro studies of transgenic mouse lines,
FVIIINull and Line h38. Wild-type mice were also run as controls. FVIIInull mice whole
blood showed no hemostatic efficacy in this system. Line h38 blood partially corrected
the hemostatic defect of FVIIInull murine blood (Figure 2.3A). To determine the amount of
Line h38 blood that was required for this effect, Line h38 whole blood was diluted with
FVIIInull blood, and ROTEM was performed (Figure 2.3B). Clot formation was detected in
as little as 1% Line h38 blood while 20% Line h38 blood was enough to bring clotting
close to that seen with whole Line h38 blood.
rFVIIa was then studied as present-day alternative therapy for patients with
hemophilia and inhibitors1,144 and the potential combination use of rFVIIa and pFVIII.
rFVIIa was added to FVIIINull whole blood to obtain at final concentration of 10 and 25 nM
and then analyzed via ROTEM assay (Figure 2.4A). 25 nM or 90 ug/kg is a
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pharmacological dose for inhibitor patients157,158. While both concentrations of rFVIIa
were able to induce clotting to some extent in this assay, only 25 nM was able to bring
parameters back near to that of wild-type; however, delay in clot time remained
suggesting that sufficient time is needed to generate sufficient FXa for hemostasis to
occur. The effect of adding both rFVIIa and Line h38 platelets in combination was also
investigated in this assay. 10 nM of rFVIIa in combination with Line h38 whole blood was
able to have an additive effect that was greater than Line h38 whole blood alone (Figure
2.4B).

In vivo studies of infused Line h38 platelets
To better understand the hemostatic value of pFVIII in vivo in FVIIInull mice, the
half-life of infused mouse platelets was determined via flow cytometry (Figure 2.5).
Isolated mouse WT platelets were either labeled with calcein-AM prior to infusion or
infused transgenic hαIIb mouse platelets were labeled with an anti-hαIIb antibody after
collection from the recipient FVIIInull mice. Blood was collected at various time points and
analyzed for percentage of remaining infused platelets. The data indicates that isolated
and infused mouse platelets had a half-life of about 22 hrs consistent with other studies
by our group and others151,159.
The hemostatic effects of infusing pFVIII-expressing Line h38 platelets into
FVIIInull recipient mice was tested after infusing sufficient platelets so that line h38
platelets represented ~15% of the total circulating platelets. This number of platelets
would represent the number of platelets that is given in a straight-forward platelet
transfusion in clinical setting160, and could be tolerated on a recurring basis. Hemostatic
efficacy was tested in the recipient mice in the tail-clip exsanguination assay that many
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groups, including ours, have used to study corrected hemostasis in FVIIInull mice118,161
(Figure 2.6). Mice were infused with Line h38 or FVIIInull platelets and then their tails
were resected to 2 mm in diameter. Mice that received Line h38 platelets, but not FVIIInull
platelets survived the overnight hemostatic challenge (Figure 2.6A). This hemostatic
effect lasted at least 72 hours post-platelet infusion. The hemostatic effects of rFVIIa
were also tested in this model (Figure 2.6B). rFVIIa was infused in FVIIINull mice at
concentration of 0.25, 1.0, and 4.0 mg/kg. As with other studies, high doses of rFVIIa
were needed to have an effect in hemophilia A mice tail bleeding and FeCl3 models153,162.
Only the highest dose was able to rescue the mice, and by 2 hours post-infusion, the
response in the tail-clip exsanguination assay had lessened.
PFVIII hemostatic efficacy was also tested in the FeCl3 carotid artery injury model
in which we had previously shown a clear defect in FVIIInull mice and a gradient of
increased hemostatic efficacy at increasing infusions of hFVIII108. Infusion of Line h38
platelets – but not non-pFVIII platelets – into FVIIInull mice was effective in decreasing
blood flow up to 48-hours post-infusion (Figure 2.7A). rFVIIa was also effective in
improving hemostasis in this model, but an additive effect with Line h38 platelets was
seen in recipient FVIIInull mice (Figure 2.7B). Line h38 mice and prophylactic pFVIII
infusions in the presence of inhibitors were tested in this model (Figure 2.7C and 2.7D).
Prior to platelet infusion, we injected mice with a single dose of an inhibitor mixture that
we previously showed fully inhibited pFVIII function in Line h38 mice (Figure 2.7C). We
confirmed these findings and defined an inhibition dose that did not inhibit hemostasis in
Line h38 mice, but did completely inhibit an infusion of Line h38 platelets to 15% (Figure
2.7D); however, the addition of rFVIIa to this pFVIII therapy was able to decrease this
inhibition.
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Discussion
The delivery of ectopic proteins by platelets to sites of vascular injury had been
proposed by our group more than 15 years ago108. Our group has designed a plateletspecific thrombolytic agent delivery strategy involving the storage of urokinase-type
plasminogen activator (uPA) within α-granules and their release at nascent thrombi as a
thromboprophylaxis agent82. These studies showed the potential of using platelets as a
potent delivery system without systemic sequelae. This type of delivery system was also
proposed to be applicable to the delivery of FVIII in hemophilia A patients with inhibitors
as well107.
In these studies, we propose that infusions of pFVIII-containing platelets may be
an effective alternative treatment for patients with severe hemophilia A and intractable
inhibitors for acute or prophylactic care. This therapy would be useful in place of
bypassing agents. These platelets would provide coverage for a longer period of time
than present-day FVIII-bypassing agents and may provide additive therapeutic potential
with inhibitors especially in the presence of inhibitors. Moreover, it would be therapy that
would avoid the potential life-threatening complication of doing platelet-directed bone
marrow gene therapy and/or can be used to help patients survive the challenges of that
process.
As a proof-of-principle for this concept of infused pFVIII platelets, we utilized Line
h38 platelets which have ~0.09 U (~75 ng) of hBDFVIII antigen per ml of mouse
blood108. Previous in vitro studies done using ROTEM technology, showed that rFVIII
can correct the hemostatic deficiency of FVIIInull blood in this system123. Whole blood
from FVIIInull mice expressing high levels (~0.2 U/ml of murine blood) of pFVIII have also
been

previously

reported

to

partially
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correct

hemostatic

function

on

thromboelastography, although still showing a prolonged initiation of clot time. We
confirm these results with our Line h38 whole blood including the prolonged clot time
(Figure 2.3). This delay in clot time is likely due to the time it takes for platelets in the
blood to become activated and release significant amounts of their granule pFVIII
content. This explanation is supported by inclusions of low doses of rFVIII where the
initial effects of very low dose rFVIII has a similar prolonged initiation of clot time (Figure
2.2). Interestingly, as little as 1% Line h38 blood added to FVIIInull whole blood was able
to have some effect in this model with 20% approximating that seen with Line h38 whole
blood, supporting the potential value of therapeutic pFVIII platelet transfusions (Figure
2.5B).
To examine additive effects of pFVIII platelet infusions with bypassing agents,
rFVIIa was used; one of the two present-day approved bypassing agents141,142,157. We
show that clot formation was detectable with as low as 10 nM rFVIIa in ROTEM studies,
while the addition of 25 nM FVIIa was required to improve maximum clot formation in
ROTEM comparable to WT levels but still showed slight deficit in clot time (Figure 2.5A).
This prolongation is consistent with rFVIIa not directly correcting the underlying
hemostatic defect, but rather bypassing the defective step in the coagulation cascade.
The addition of 10 nM rFVIIa to Line h38 blood showed an additive effect with a
decrease in initiation of clot time, however the lag in clot time was still present (Figure
2.5B). This failure to correct the clot time may again be in part due to the need for
platelet activation and pFVIII release to begin to have pFVIII contribute to overall
hemostasis. In addition this delay in hemostasis is due to low levels of either
supplemental rFVIII (Figure 2.2) or rFVIIa (Figure 2.4).
Prophylactic infusions of pFVIII platelets were further tested in vivo in two distinct
assay systems beginning with the tail-clip exsanguination assay. The recipient infused
39

FVIIInull mice survived an overnight tail-clip exsanguination assay, which, in agreement
with prior observations, was 100% lethal in non-transfused FVIIInull mice or mice infused
with non-pFVIII platelets. The hemostatic effects of infusing pFVIII-expressing Line h38
platelets into FVIIInull recipient mice was sufficient to result in ~15% of the circulating
platelets being from Line h38. Such a level of infused platelet should be achievable
clinically and a correction of this level had shown hemostatic efficacy in vitro (Figure
2.3). Beginning at 1 and extending to 72 hours post-infused Line h38 platelets (Figure
2.6A), there was improved survival in this tail-clipping hemostatic model in FVIIInull mice.
This effect was not due to simply having infused platelets into the FVIIInull mice (Figure
2.6A). We also found that the half-life of infused platelets prepared by us was ~22 hours
(Figure 2.3), consistent with half-lives reported for infused murine platelets by others. By
72-hours post-infusion of 15% Line h38 platelets, we anticipate that <2% of the
circulating platelets would be Line h38-derived. In contrast to this infusion of pFVIII
platelets, infusion of rFVIIa was ineffective at rescuing recipient FVIIInull mice from tailclip exsanguination even 0.25-hour post-infusion unless a high dose of 4 mg/kg rFVIIa
was given, but even here, hemostatic efficacy was mostly gone 1.5-hours post-infusion
(Figure 2.6B) consistent with the known short half-life of human rFVIIa in mice. It is worth
noting that cessation of bleeding in the high dose rFVIIa arm was observed early in the
assay, after the tail clip, indicating residual levels of rFVIIa might have improved their
survival (data not shown).
The FeCl3 carotid artery injury model was also used to study in vivo hemostatic
challenges in FVIIInull mice. Previous work from our group has shown a positive
correlative relationship between infused human rFVIII and decreased blood flow108. This
assay can be completed within 30 minutes, and thus would allow studies of the additive
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effects of pFVIII with rFVIIa. Mice infused with Line h38 platelets saw therapeutic
efficacy for at least 48-hours post-infusion (Figure 2.7A).
We believe that the differences between efficacy of pFVIII platelets by the two in
vivo assays is the greater sensitivity of the tail-clip exsanguination assay to low levels of
pFVIII as stasis likely occurs in the tails of these animals allowing greater efficacy to the
available pFVIII161. Nevertheless, if the half-life of these platelets and their therapeutic
efficacy in mice, were extrapolated to humans, one would imagine a therapeutic window
of 2-3 weeks, assuming a human platelet half-life of ~7-10 days. Line h38 platelets
showed a combinatorial effect with rFVIIa (Figure 2.7B), indicating that this bypassing
agent could be added to patients on pFVIII infusion prophylaxis therapy in settings of
acute bleeds. More importantly, prophylactic pFVIII infusion was able to be effective in
the setting of inhibitor (Figure 2.7D), this effect was also enhanced with the addition of
rFVIIa.
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Figure 2.1 Rotational Thromboelastometry (ROTEM) parameters
Example of typical ROTEM data and parameters obtained from running in vitro
experiment. Graph indicates the time it takes to initiate clotting: clot time (CT), the time it
from when clotting starts to when clotting reaches 20mm of firmness (green area): clot
forming time, the maximum stiffness of the clot: maximum clot firmness (MCF), and the
steepness of the clotting curve: alpha angle.
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Figure 2.2 Addition of soluble rFVIII improves clotting in in vitro ROTEM assay
beginning with FVIIInull blood.
Studies similar to Figure 2.1 except that the noted concentrations of rFVIII were added to
of FVIIInull (KO) whole blood to achieve the concentrations noted. Each curve represents
4 independent studies.
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Figure 2.3 ROTEM analysis of WT, FVIIInull and Line h38 mice whole blood as well
as studies of admixtures of Line h38 into FVIIInull whole blood.
Whole blood from WT (black), Line h38 (brown), and FVIIInull (yellow, KO) mice were
studied by ROTEM in (A) and (B). (A) Each curve represents 5 independent studies. (B)
Same analysis as (A) in which Line h38 whole blood was added into FVIIInull to result in
1, 5 or 20 percent levels of Line h38 platelets in the blood mixture. Each curve
represents 4 independent studies.
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Figure 2.4 Additive effect of rFVIIa and pFVIII by ROTEM.
ROTEM analyses were performed as in Figures 2.1-2.3. (A) rFVIIa was added to FVIIInull
mouse whole blood to bring the final concentrations to 10 and 25 nM. (B) Line h38 whole
blood in the absence (red) and presence (purple) of 10 nM rFVIIa added were compared
to FVIIInull mouse whole blood with 10 nM rFVIIa (blue). WT (black) and FVIIInull (yellow)
mouse blood were used as positive and negative controls, respectively, in both (A) and
(B). Each curve represents 4 independent studies in both (A) and (B).
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Figure 2.5 Half-life of isolated mouse platelets infused into FVIIInull mice.
(A) Half-life based on infusing 1-4x108 human hαIIb-expressing mouse platelets into
FVIIInull mice. Total hαIIb-expressing platelets were tracked over 72 hours via flow
cytometry. Measurement of remaining infused human platelets normalized to level at 5minutes post-infusion. Mean ± 1 SEM are shown. N = 4 independent studies. (B)
Calcein-AM 4x108 loaded WT platelets infused into FVIIInull mice. Percent of circulating
platelets that contained calcein are shown. Mean ± 1 SEM are shown. N = 3
independent studies.
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Figure 2.6 Survival post Line h38 platelet and rFVIIa infusion in the tail-clip
exsanguination assay.
(A) and (B) tail-clip exsanguination assay with expiration assessed 16-hours post-tail
clip. (A) On the left part of the graph, WT, FVIIInull and Line h38 mice underwent tail-clip
exsanguination. On the right, FVIIInull mice were infused with 15% Line h38 platelets and
then underwent tail-clip exsanguination at 1, 24, 48, and 72-hours post-infusion. Percent
of animals surviving of N = 4 animals per arm is shown for each time point. (B) On the
left part of the graph, WT, FVIIInull and Line h38 mice underwent tail-clip exsanguination.
On the right, mice were infused with 0.25, 1 and 4 mg/kg rFVIIa, retro-orbitally 15
minutes prior to tail resection plus additional mice studied at 4 mg/kg rFVIIa 1.5 hours
after the infusion with N = 4 animals per arm. Percent of animals surviving of N = 4
animals per arm is shown for each concentration.
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Figure 2.7 Efficacy of Line h38 platelet in the FeCl3-carotid artery injury model.
FeCl3-carotid artery injury studies were studied using a 20% FeCl3 solution and a threeminute injury as described109,152. Area under the curve (AUC) of subsequent blood flow
was measured. In all studies, P values determined by one-way ANOVA. (A) WT, FVIIInull,
Line h38 mice were studied as were FVIIInull mice infused with either WT or Line h38
platelets to achieve 20% of the circulating platelets in the recipient. Those animals
infused with Line h38 platelets were studied up to 72 hours later. Mean ± 1 standard
error of the mean (SEM) are shown with N = 5 animals per arm. (B) Same as in (A) with
studied FVIIInull mice infused with the indicated amounts of Line h38 platelets and rFVIIa.
Mean ± 1 SEM are shown with N = 5 animals per arm. (C) Line h38 mice were infused
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with varying concentrations (1.0, 1.5, or 2.0 µg/g of mice) of the inhibitor mixture prior to
the FeCl3 injury. Mean ± 1 SEM are shown with N = 5 animals per arm. (D) FVIIInull and
Line h38 mice were studied in the FeCl3-carotid artery injury model as in (A). FVIIInull
mice were also infused with ~15% Line h38 or WT platelets and with varying
concentrations of the inhibitor mixture (0.2, 0.5, or 1.0 µg/g of mice) ± 1 mg/kg of rFVIIa
prior to the FeCl3 injury. Mean ± 1 SEM are shown with N = 5 animals per arm.
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Chapter 3 – Generation and in vitro and in vivo characterization of iMks
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Abstract
Using lentivirus to express genes in cells that normally do not express them has been a
hallmark of gene therapy. To this end, I have used separate lentiviral constructs to
express the three FVIII variants; hBDFVIII, hBDFVIIIRH and hBDFVIIIΔ and then
transduce them into differentiating induced pluripotent derived megakaryocytes (iMks).
hBDFVIIIRH and hBDFVIIIΔ have greater hemostatic efficacy and biology activity in
comparison to hBDFVIII due to a mutation in a PACE/Furin cleavage site. This chapter
details the generation of human iPSCs (WT control) from human bone marrow cells,
their maintenance, and differentiation into iMks. In addition, this chapter will outline a
protocol for making viral vectors and their use in transducing HPCs that will are
differentiated into iMks. Next, I characterize these FVIII-expressing iMks (pFVIII-iMks)
and investigate the effects of expressing FVIII on Mks F8 mRNA levels, injury to the
iMks and apoptosis, iMk responsiveness to agonists/activation. Lastly, I describe these
FVIII-expressing iMks’ efficacy in in vitro and in vivo assays of clot formation and
thrombosis. Ultimately, these studies indicate the potential use of iMks in infusion
therapy for severe Hemophilia A patients.
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Introduction
Since the advent of iPSCs in 2006, many researchers have used this technology
to model rare diseases, research areas of regenerative medicine, and develop potential
therapeutics. iPSCs are made by ectopically expressing four transcription factors, Oct-4,
Sox2, Klf4 and c-Myc, in somatic cells99,100. Since the inception of this technology,
delivery systems for the key reprogramming factors have become more efficient and
safe, in part, through the development of inducible single expression cassettes.
Upon reprograming, iPSCs share many features with ES cells and have the
ability be differentiated into almost any cell type, which gives them a wide array of
applications. In addition, they self-renew, allowing for a virtual unlimited supply of cells of
interest after reprogramming100. Because of these key features iPSCs have become
attractive tools in almost all areas of research. In addition, iPSCs have the benefit of
being able to be derived from somatic cells of healthy individuals as well as patients with
rare diseases, allowing for their use in personalized medicine. To this end, researches
have been able to further gene manipulate these cells for potential therapeutic benefit.
The ability of these cells to differentiate into a myriad of functional cell types has
been exploited extensively, including benign hematology163,164. Protocols have been
developed to differentiate iPSCs into mesoderm layer cells and HPCs. These HPCS can
then be further differentiated to any subsequent linage cell, including terminal
hematopoietic cells like Mks165,166. Some of the earlier hematological applications of
iPSCs included the study of sickle cell anemia167 and Fanconi anemia168.
Our laboratory has utilized iPSCs, not only to differentiate them into Mks to study
rare diseases like Glanzamann’s thrombasthenia, but also to correct the underlying
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defect. For Glanzmann thrombasthenic iPSCs, we showed that expression of the human
ITGA2B cDNA under the human Gp1ba promoter can drive sufficient αIIb expression to
correct the thrombasthenic disorder in two different patient derived lines102. The
expression construct was inserted using zinc finger nuclease (ZFN) technology into the
adenovirus associated vector site (AAVS) 1 “safe harbor” locus and shown to correct
αIIb expression in an Mk-specific fashion. More recently, our laboratory was able to
develop iPSC lines derived from a patient with Paris Trousseau syndrome (PTSx), which
underexpressed

FLI1.

In

parallel

lines,

using

TALEN

technology,

FLI1

was

heterozygously knocked out in a WT line and another line was established where FLI1
overexpression was driven in a Mk-specific fashion. These studies targeted FLI1 using
ZFN technology to the AAVS1 locus and provided new insights into FLI1 biology, its role
in PTSx and FLI1’s potential use in optimizing platelet release from iMks after infusion
into recipient mice101.
While both these studies from my group utilized an AAVS-1 targeting method,
lentiviral targeting methods have also been used to express genes into iPSCs. Gene
therapy through lentiviral expression has a number of advantages for transgene
expression169. Lentiviral vectors are able to easily integrate into a large variety of cell
types, allowing for efficient transfection of the desired genes170. Once integrated, these
vectors are able to express high levels of the transgene with limited silencing169. These
vectors can also express genes in a tissue-specific manner with the appropriate
inclusion of a tissue-specific promoter109. In recent years, their use has become more
efficient and safe through the use of 3 and 4 vector systems for producing virus as well
as the development of self-inactivating vectors171-173. Lentiviruses, however, can cause
toxicity to targeting cells when used in large quantities174. Furthermore, off target
integration of the vectors is also an area of concern175,176.
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Because of their benefits and ease of use, our group has also utilized lentiviral
vectors in experiments to express FVIII variants in Mks of FVIIInull mice and in human
and canine Mks as well109. We found that significant levels of hBDFVIII could be
produced within Mks and subsequently platelets of these animals and that this
expression could aid in hemostasis of FVIIInull mice after injury. Previously, we developed
3 vector plasmids that the contained hBDFVIII, inactivation resistant FVIII (IRFVIII), or
canine (c) cBDFVIII under the control of the GPIBA promoter. Although the level of
IRFVIII and cBDFVIII antigen was lower than hBDFVIII and Line h38 mice, IRFVIII and
cBDFVIII showed higher hemostatic efficacy152. Noting the success of cBDFVIII in these
studies, our group utilized a human FVIII variant that had an analogous sequence in a
PACE/Furin cleavage site, hBDFVIIIRH, developed by Drs. Valder Arruda and Denis
Sabatino42,88. Comparing cBDFVIII, hBDFVIII, and hBDFVIIIRH, we found hBDFVIIIRH had
better hemostatic efficacy than hBF8. Additionally, we showed that FVIII expressed in
Mks and platelets could have adverse effects on the developing cells, especially when
using cBDFVIII. Previously, cBDFVIII had shown to be expressed in BHK cells at three
times the level of hBDFVIII, but we found the opposite using Mks from mice, humans or
dogs109. These cFVIII-Mks were more apoptotic as noted via TUNEL assay, in
comparison to FVIIInull Mks. It was also found that thrombopoietin (TPO) levels in
transgenic cBDFVIII animals were elevated, suggesting that these post-BMT mice were
compensating for a detrimental effect of cBDFVIII on megakaryopoiesis109. Taken
together, we hypothesized that the level of cBDFVIII expressed in Mks could cause them
to become apoptotic, and that these deleterious effects may need to be considered
when developing pFVIII-based therapy.
To date only one report has tried to express FVIII in iMks. Using human artificial
chromosome (HAC) vector, Yakura, et al., used an integration-free method to express
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FVIII driven by the CXCL4 promoter177. IPSCs were made from hemophilia A mouse
cells and differentiated into iMks on OP9 stromal cell cultures after HAC targeting with
Sendai virus (SeV). This group showed they could get Mks-specific expression of FVIII
after the addition of TPO during iMk differentiation. While they showed expression of
FVIII in Mk, this detection was limited to mRNA. This group was unable to show any
expression of functional FVIII protein. In addition, this study did not show the
functionality and efficacy of pFVIII-iMks in any FVIIInull models of thrombosis or
hemostasis177. Because of these limitations, one is left to wonder whether or not these
Mks or the FVIII they contained could produce platelets that would be able to correct the
FVIIInull phenotype.
In an attempt to express high levels of FVIII in my iMks, I attempted to use the
Gp1ba promoter-driven FVIII cDNA inserted into the AAVS1 in iPSCs, but this strategy
did not lead to sufficient FVIII expression (but see Chapter 4). My subsequent studies in
this chapter used lentiviral vector studies to drive expression in iMks of hBDFVIII or
hBDFVIIIRH or hBDFVIIIΔ after viral transduction into HPCs from differentiated WT
iPSCs. These transduced HPCs were differentiated into FVIII expressing iMks (pFVIIIiMks). pFVIII-iMks were then characterized in vitro and then tested for hemostatic
efficacy both in in vitro ROTEM and in vivo FeCl3 assays in the setting of hemophilia A.

Materials and Methods
Generation, confirmation, and maintenance of WT iPSC line
WT (WTBM1-8) iPSC used in subsequent experiments was generated as
previously described102,178. Bone marrow cells were purchased from the stem cell core at
the University of Pennsylvania (Philadelphia, PA). CD34+ cells were selected and
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seeded onto a 35-mm plate, pre-coated with 5 µg/ml polybrene. pHAGE-hSTEMCCA
(Figure 3.1), which contains the four transcription factors, OCT4, SOX2, KLF4, and cMYC essential for reprograming99. This vector was co-transfected with a vector
containing reverse tetracycline transactivator protein (rTTA), pHAGE2-CMV-rTTA that
allowed for cell reprograming after the addition of doxycycline178. Post-incubation, viral
media was replaced with media suitable for iPSC grow, consisting DMEM/F12 (Gibco),
20% KnockOut Serum (Invitrogen), 1 mM L-glutamine (Sigma-Aldrich), 1% nonessential
amino-acid solution (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma-Aldrich), and 10
ng/ml basic fibroblast growth factor (bFGF) (R&D Systems). To select for properly
transfected cells, 1 µg/ml doxycycline was added to the iPSC media for 3 weeks. Media
was removed and replaced daily until individual drug resistant clones were present.
Clones were picked and allowed to culture further179.
Proper reprograming and analysis of pluripotency was confirmed through
karyotyping of genomic DNA, analysis of ES cell surface markers, and teratoma
formation of iPSCs. Karyotyping was performed by Cell Line Genetics (Madison, WI)
(Figure 3.2A). 6 X 106 iPSCs were injected subdermally into NOD-SCID mice (strain
250, Charles River) to assess teratoma formation. Tumors were collected, fixed and
stained using hematoxylin and eosin, and assessed for germ layers as previously
described102,165,178 (Figure 3.2B). To study pluripotent markers, cell expression of stagespecific embryonic antigen (SSEA) 3, SSEA4, Tumor-related Antigen (TRA)-1-60 and
TRA-1-81 antigens were investigated via flow cytometry using a BD FACSCanto II (BD
Biosciences). SSEA3 Alexa Fluor (AF) 488, SSEA4 AF 647, TRA-1-60 AF 488, and
TRA-1-81 AF 647 (Biolegend) antibodies were used to see relative amounts of antigens
(Figure 3.2C). Proper cell morphology of iPSC colonies and cultures is indicated in
Figure 3.2
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Successfully reprogrammed cells were cultured and maintained as previously
described166. Six-well culture dishes were coated with 0.01% gelatin at 37°C for 1 hour
prior to addition of irradiated mouse embryonic fibroblasts (MEF) feeder-layer. This
feeder-layer created a support, secreting factors needed for iPSC survival. After
addition, MEFs were allowed to adhere to the plate for a minimum of 4 hours at 37°C in
5% CO2 prior to use of the plate. iPSC colonies were maintained on MEF plates (Figure
3.3A) and passaged every 3-4 days. To passage feeder cultures, cells were incubated
with Accutase up to 5 minutes at 37°C to detach cells from the plate. Detached cells
were then centrifuged at 1200 rpm for 3 minutes before passaging at the appropriate
split ratios, ranging from 1:8 to 1:24, in iPSC medium. 10 µM Y-27632 dihydrochloride
Rho Kinase (ROCK) inhibitor (Tocris) was added to the media overnight. The following
day, iPS media lacking ROCK inhibitor was substituted and replenished daily.
After several successful passages on feeder-layer MEFs were transitioned to a
feeder-free culture (Figure 3.3B). Splitting ratios on feeder free cultures ranged from 1:2
to 1:12. Prior to passaging, six-well plates were treated with diluted Matrigel hESCqualified matrix (Corning) for 1 hour. To passage feeder-free cultures, cells were washed
with DMEM/F12 media and were allowed to incubate with Dispase (STEMCELL
Technologies) at 37°C for up to 6 minutes or until the edges of the iPS colonies began to
detach. Cells were then washed twice with DMEM/F12 media and then fresh mTRS-1
media was added (STEMCELL Technologies). Colonies were then removed by scarping
the well with cell scraper (SARSTEDT) and then split to the appropriate ratio and
transferred to matrigel plates. mTSR-1 cell media was removed and replenished daily.
All IPSCs were maintained at 37°C at 5% O2 and 5% CO2.

Vectors used for reprogramming and lentiviral production
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Previously described self-inactivating (SIN) lentriviral constructs180 used in these
studies included the hBDFVIII (BD), the hBDFVIIIR1645H (RH), the hBFVIIIΔ (Δ), and
eukaryotic green fluorescent protein (eGFP), each driven by the murine Ccxl4 proximal
promoter109. Infectious viral stocks were produced through transient infection of human
embryonic kidney 293T cells with the psPAX2 packaging vector, the pMD2G vesicular
stomatitis virus glycoprotein envelope vector, and the appropriate lentiviral FVIII plasmid
(Figure 3.4) at a DNA ratio of 2:1:4 respectively. Plasmids were co-transfected into 15cm
dishes of 9x106 293T cells using polyethylenimine (PEI) (Polysciences). PEI to DNA
volume ratio was 3:1. Viral particles were collected from the supernatant 48-hours posttransfection, and concentrated by ultracentrifugation at 30,000g for 2 hours (Figure 3.5).
Titering of final lentiviral infectious stocks was performed at the Fred Hutchinson Cancer
Research Center as follows: HT1080 cells were plated in DMEM growth medium in 12well plates. The following day, cells were transduced with dilutions of the viral vector.
The cells were subsequently kept in culture for 10 days in which they were passaged at
a 1:5 split twice. DNA was extracted from cells and the percentage of viral genome
copies were analyzed by qPCR as previously described109.

iPSC differentiation into iMks
IPSCs cultured on feeder-free cultures were utilized to differentiate into Mks.
Differentiation of WT IPS line was performed as previously described102,165,166.
Differentiation was an 8 day process that began with iPSCs and ended up HPCs. Prior
to the start of differentiation, six-well plates were coated with 1:3 Matrigel
(Corning):DMEM/F12 media and allowed to incubate at 37°C for 30 minutes. Feed-free
cultures were then split onto these plates at a ratio of 1:3 to 1:12. Cells were then
allowed to re-attach overnight prior to differentiation.
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Differentiation began on day 0 (D0). Prior to D0 media being added to the
differentiation plates, the cells were re-fed with mTSR-1 media for 2-4 hours to remove
any debris. See Table 3.1 for full details of the various differentiation media. Cells were
washed with Roswell Park Memorial Institute media (RPMI, Gibco) before feeding with 4
ml per 35-mm dish of D0 media. At D2, cells were again washed with RPMI prior to 4
mls per 35-mm dish of D2 media being added. On D4, cells were fed 4 ml per 35-mm
dish of D4 media. Two days later, D4 media was removed and D6 media added. The
day after D6 media is added, the unattached, suspended HPCs were collected from the
supernatant. D7 media was then added, and HPCs were collected on both D7 and D8.
After D8, plates were discarded and HPCs can be either be further differentiated and
matured into iMks as previously described or infected with lentivirus and then
differentiated. HPCs are added into iMk differentiation media for up to 7 days166.

Establishing pFVIII-iMks
HPCs (5-10x105 per well) were transfected with the FVIII-expressing or control
lentiviral vectors at a multiplicity of infection of 1-10 via spin infection at 2000g for 2
hours at 37°C in a 12-well non-tissue culture plate (BD Pharmingen) coated with 10-20
µg cm-2 RetroNectin (Takara Bio) in iMk differentiation media as previously
described109,152. Viral particles were washed off the cells 24 hours post-infection. Cells
were placed in fresh iMk differentiation media for 5 days, and the resulting iMks were
characterized in vitro or used to study pFVIII biology in vitro and in vivo.

Viral integration number in pFVIII-iMks
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DNA was extracted from pFVIII-iMks using DNeasy® Blood and Tissue Kit
(Qiagen). Viral integration was determined via Lenti-X™ Provirus Quantitation Kit
(Clontech). Total RNA was isolated from 2x106 iMks using RNeasy Micro Kit (Qiagen).
Total RNA (500 ng) from each sample was used to generate cDNA using High Capacity
Reverse Transcription Kit (ABI) used according to manufacturer’s instructions.

mRNA analysis
Message RNA level of target genes in final iMks was determined by quantitative
RT-PCR using Taqman Probes with TaqMan® Fast Advance Master Mix (ABI) via 7900H
T Real-Time Cycler. Taqman Probes used were: FVIII (F8) Hs00252034_m1, integrin
alpha-IIb (ITGA2B) Hs01116228_m1, Tata Binding Protein (TBP) Hs00427620_m1, and
platelet factor 4 (PF4) Hs00427220_g1. Relative transcript levels were quantified using
the 2-ΔΔCT method181 and calculated against TBP as the standard.

Flow cytometry analysis of iMks
Day 6 pFVIII-iMks, NTC and eGFP controls were stained and analyzed surface
markers and degree of apoptosis on FacsCanto (BD Biosciences) and further analyzed
using FlowJo software as previously described. Antibodies used in these studies are
listed in Table 3.2.

pFVIII antigen level in pFVIII-iMks
FVIII antigen levels in iMks were determined using an ELISA for hFVIII as
previously described. Levels were compared to recombinant full-length hFVIII (Advate,
Shire) and pFVIII levels in Line h38 Mks.
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Apoptotic studies of pFVIII-iMKs
Apoptotic changes in pFVIII-iMks was done in part by TUNEL-labeling using the
APO-bromodeoxyuridine (BrdU) TUNEL Assay Kit (Invitrogen) as per manufacturer’s
directions. Samples were stained and analyzed via flow cytometry using APC-labeled
anti-CD42b (BD Biosciences) and AlexaFluor-488 labeled anti-BrdU for degree of
apoptosis. All samples were compared to non-transduced controls. To further investigate
apoptosis, 1x106 iMks samples were incubated with 5 µl annexin V-FITC (BD
Biosciences), 10 µl APC-labeled anti-CD42b in 100 µl Tyrode’s buffer (Sigma) with 0.1%
bovine serum albumin (BSA, Thermo) at room temperature (RT) for 30 minutes. Post
incubation, cells were washed twice and then resuspended in Tyrode’s buffer that
contained 0.1% BSA. Annexin V binding and CD42b levels were analyzed via flow
cytometry. iMks were also stained concurrently with anti-CD41 and anti-CD42b (both BD
Biosciences) antibodies to measure the loss of gylcocalicin within CD42, an indicator of
Mk injury182.

iMk responsiveness to thrombin
To examine in vitro-responsiveness of iMks to an agonist, 1x106 iMks were
incubated with 1 unit of thrombin/ml (T8885-1VL, Invitrogen) in Tyrode’s buffer with 0.1%
BSA in a final volume of 100 µl containing 1:2000 APC-labeled anti-CD42b antibody and
FITC-labeled PAC-1 (BD Biosciences) as previously described102. The samples were
incubated at 37°C for 30 minutes. Post incubation, 500 µl of ice-cold 0.1% Tyrode’s
buffer was added. PAC-1 and CD42b binding were then analyzed via flow cytometry.

In vitro hemostatic studies with pFVIII-iMks
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ROTEM studies of pFVIII-Mks were performed by adding 10 µl of medium
containing 5x103-5 pFVIII-iMks expressing hBDFVIII or hBDFVIIIRH, which has been
shown by our group and others to have increased specific activity and hemostatic
efficacy, to 110 µl of whole FVIIInull mouse blood. Negative controls were iMks
transfected with no lentivirus, the eGFP-expressing lentivirus or phosphate-buffered
saline (PBS, Gibco) added to the same volume of blood. ROTEM studies were
performed as described in Chapter 2.

In vivo hemostatic studies with pFVIII-iMks
In vivo FeCl3-carotid artery injury studies using FVIIInull mice after xenotransfusion
of human iMks were similar to the studies with Line h38 platelets, except that the
recipient FVIIInull mice were pre-treated with clodronate liposomes (Encapsula
NanoSciences) 24 hours prior to iMk infusion, to deplete macrophages and extend the
half-life of the infused iMks and their released platelets. The percent human platelets
circulating post-iMk infusion were determined following retro-orbital blood draws by flow
cytometry using species-specific anti-αIIb antibodies, as we previously described151,183.
Recipient FVIIInull mice received 5-10x106 iMks expressing hBDFVIII, hBDFVIIIRH, or
eGFP infused via the jugular vein in 200 µl total volume of PBS.

Statistical analysis
Statistical differences between arms were determined using a two-sided
Student’s t-test or analysis of variance (ANOVA) with Bonferroni, Dunnett’s or Tukey’s
corrections of multiple comparisons, when appropriate. PRISM 7.0 (Graphpa) was used
to calculate statistical significance. P-Values ≤0.05 were considered significant.
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Results

FVIII expression in pFVIII-iMks
The iPSC line that we utilized had been previously used by our group and shown
to be capable of differentiating into an evaluable number of iMks101,102. HPCs were
transduced with the previously described Cxcl4-proximal promoter driven lentiviral
vectors that express hBDFVIII (termed below BD), hBDFVIIIRH (termed below RH),
hBDFVIIIΔ (termed

Δ),

or

eGFP.

A

schematic

showing

iPSC

hematopoietic

differentiation, FVIII lentiviral transduction and downstream applications is shown in
Figure 3.6. On Day 6 of iMk differentiation, lentiviral copy numbers of transduced cells
were determined and shown not to be significantly different between the four vectors,
although the highest level was seen for the RH-iMks (Figure 3.7A). F8 mRNA was
highest for BD (p<0.001, Figure 3.7B), while RH and Δ showed similar levels. Although
BD had the highest message level, FVIII antigen per cell by ELISA was ~50% higher for
RH (p<0.01, Figure 3.7C). In addition, Line h38 Mks expressed at 2 orders of magnitude
higher than pFVIII-iMks.

In vitro characterization of lentiviral pFVIII-iMks
Our previous studies suggested that ectopically expressed FVIII in Mks was
harmful to the developing cells. To determine if damage and level of apoptosis to iMks
occurred in this system, examination of cells for bromo-deoxyuridine staining via TUNEL
assay (Figure 3.8A) and annexin V binding (Figure 3.8B) was completed. No difference
was observed in these studies between pFVIII-iMks and controls. In addition, the health
63

of the pFVIII-iMks was analyzed by responsiveness to agonist stimulation and no
difference was observed (Figure 3.9A). iMks were further analyzed for percent of the
CD41+ pFVIII-iMks that were also CD42b+ – an indicator of undamaged Mks (Figure
3.9B) – was done, comparing pFVIII-iMks to non-transfected iMks controls. mRNA levels
of endogenous genes CXCL4 and ITGA2B genes were also investigated and showed no
difference between FVIII-containing iMks, and NTC and eGFP controls (Figure 3.10A
and 3.10B, respectively).

In vitro studies with human pFVIII-iMks
ROTEM studies were done with pFVIII-iMks added to FVIIInull murine whole blood
and demonstrated that as few as 5x103 pFVIII-iMks added to 110 µl of whole blood can
improve hemostasis compared to the addition of iMks not expressing FVIII (Figure 3.11A
and 11B). The RH-iMks showed greater efficacy than BD -iMks as indicated by a shorter
clotting time and increased α-Angle (Figure 3.11A and 11B). The addition of 10 nM
rFVIIa showed a combinatorial effect with the pFVIII-iMks, further improving hemostasis,
but not fully correcting it as the clotting time notably remained prolong (Figure 3.11C),
supporting the Line h38 platelet data shown in Figure 2.4.

In vivo studies with human pFVIII-iMks
Infused iMks released detectable human platelets with a half-life of ~4 hours
(Figure 3.12A). This short timeframe precluded tail-clip exsanguination studies, but
allowed us to perform FeCl3 carotid artery studies initiated within 30 minutes after iMk
infusion. Both WT and RH iMks improved hemostasis significantly compared to non-
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pFVIII-iMks, although none of these mice developed occlusive thrombi (Figure 3.12B).
As in the ROTEM studies, RH iMks improved hemostasis better than BD iMks.

Discussion

Our laboratory has shown that infused Mks into mice release functional platelets
after being entrapped in the lungs71. These platelets respond to platelet agonists and are
able to take part in hemostasis during hemostatic challenge. These iMk-released
platelets are also functional. Recently using in situ microscopy, it has shown that
endogenous Mks in mice also travel to the lungs after being released from the marrow
and release platelets that account for half of the daily production of platelets71. Thus
infused iMks-released platelets in the lungs are likely to represent as good as platelets
as one can obtain from in vitro-grown megakaryocytes and provide insights into the
applicability of pFVIII-iPlatlets (iPlts) in the care of patients with hemophilia A.

In vitro characterization of pFVIII-iMk
Previous studies from our group showed that FVIII expressed at high levels
within Mks, especially cFVIII, can be deleterious to the developing cell. We therefore
examined using various markers of apoptosis and iMk health to see whether the pFVIIIMks were injured by the expressed FVIII. These studies found no indication of apoptosis
or other injuries (Figure 3.8-3.10). The health of these iMks is likely in part due to human
pFVIII not being as injurious to Mks as cFVIII and in part to the fact that the level of
human pFVIII expressed in these iMks was low perhaps 1% of that achieved in Line h38
transgenic mice Mks.
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In vitro hemostatic studies with human pFVIII-iMks
ROTEM studies were completed with pFVIII-iMks added to FVIIInull murine whole
blood and demonstrated that as few as 5x103 pFVIII-iMks added to 110 µl of whole
blood can improve hemostasis compared to the addition of iMks not expressing FVIII.
This would be consistent with as few as 105 iMks being sufficient to achieve hemostatic
effect in a 30 gm mouse. If each iMk released ~100 iPlts that would mean that ~107
human iplts or ~1% of the concurrent ~2x109 murine platelets would be sufficient to
demonstrate hemostatic efficacy in the intact mouse. Importantly, these in vitro
hemostatic studies also supported that RH pFVIII were more effective than WT pFVIII
released from iMks. The released pFVIII from iMks showed combinatorial hemostatic
improvement with rFVIIa, further supporting the Line h38 platelet data shown in Figure
2.4 and the utility of pFVIII infusion in the care of patients with hemophilia A.

In vivo hemostatic studies with human pFVIII-iMks
During these experiments, there was no available FVIIInull murine model on an
immune compromised background that was available for infusion studies, so we infused
iMks into clodronate liposome-treated FVIIInull mice to improve human platelet half-life by
reducing phagocytic removal of the human cells and their released platelets. This was a
successful model system although it is likely that circulating pre-activated platelet-like
particles released in culture as we previously described are also present, though our
prior studies suggest that they poorly contribute to hemostasis183. Clearly, these studies
should be repeated in FVIIInull mice that are on an immunocompromised background and
such studies are underway having obtained such mice from Dr. Shu-Wha Lin at Taiwan
University.
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The relatively short half-life of the iPlts in clodronate liposome-treated FVIIInull
mice precluded tail-clip exsanguination studies, but allowed us to perform FeCl3 carotid
artery studies initiated within 30 minutes after iMk infusion. Both hBDFVIII and
hBDFVIIIRH iMks improved hemostasis significantly compared to non-pFVIII-iMks,
although none of these mice developed occlusive thrombi (Figure 3.12B). As in the
ROTEM studies, hBDFVIIIRH iMks improved hemostasis better than hBDFVIII iMks,
further supporting the application of this variant or others showing greater specific
activity in any therapy involving pFVIII treatment in hemophilia A.

67

Tables
Table 3.1 Composition of iPSC and megakaryocyte differentiation medias
Component
RPMI (P/S+Glut)
Ascorbic Acid (fresh)
MTG (fresh)
BMP4
VEGF
CHiR (GSK b3 inhibitor)
RPMI (P/S + Glut)
SP34 (P/S + Glut)
Ascorbic Acid (fresh)
MTG (fresh)
VEGF
BMP4
bFGF-100
StemPro 34 (P/S+Glut)
Ascorbic Acid (fresh)
MTG (fresh)
VEGF
Day 6,7,8 (D6,7,8)
Component
SFD
Ascorbic Acid
(fresh)
MTG (fresh)
VEGF
bFGF-100
TPO
IL-6
Flt3L
SCF

Working
Concentration
Day 0 (D0)

Final
Concentration

Volume
(1 plate)

5 mg/mL
26 µL/2 mL IMDM
10 µg/mL
50 µg/mL
10mM
Day 2 (D2)

10 µL /mL
3 µL /mL
5 ng/mL
50 ng/mL
1 µM

24 mL
240 µL
72 µL
12 µL
24 µL
2.4 µL

10 µL/mL
3 µL/mL
50 ng/mL
5 ng/mL
20 ng/mL

12 mL
12 mL
240 µL
72 µL
48 µL
12 µL
4.8 µL

10 µL/mL
3 µL/mL
15 ng/mL

24 mL
240 µL
72 µL
7.2 µL

5 mg/mL
26 µL/2 mL IMDM
50 µg/mL
10 µg/mL
100 µg/mL
Day 4 (D4)
5 mg/mL
26 µL/2 mL IMDM
50 µg/mL

Working
Concentration

Final
Concentration
10 µL/mL

Day 6
(1 plate)
18 mL
180 µL

Day 7
(1 plate)
24 mL
240 µL

Day 8
(1 plate)
30 mL
300 µL

5 mg/mL
26 µL/2 mL IMDM
50 µg/mL
100 µg/mL
50 µg/mL
10 µg/mL
50 µg/mL
100 µg/mL

3 µL /mL
50ng/mL
100ng/mL
50ng/mL
10ng/mL
25ng/mL
25ng/mL

54 µL
18 µL
18 µL
18 µL
18 µL
9 µL
4.5 µL

72 µL
24 µL
24 µL
24 µL
24 µL
12 µL
6 µL

90 µL
30 µL
30 µL
30 µL
30 µL
15 µL
7.5 µL
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Table 3.1 Cont.
iMk differentiation media
Component

Working
Concentration

Final
Concentration

Volume
(1 plate)
12 mL

5 mg/mL
26 µL/2 mL IMDM
100 µg/mL
50 µg/mL

10 µL/mL
3 µL/mL
25 ng/mL
100 ng/mL

120 µL
36 µL
3 µL
24 µL

SFD
Ascorbic Acid (fresh)
MTG (fresh)
SCF
TPO

Ascorbic acid (Wako Chemicals)
BFGF: Basic fibroblast growth factor (R&D Systems)
BMP4: Bone Morphogenic Protein 4 (Stemgent)
CHIR: Synthase Kinase 3 inhibitor CHIR (Tocris)
FLT-3L: Tyrosine Kinase 3 Ligand (Gibco)
Glut: L-glutamine (Sigma-Aldrich)
MTG: monothiolglycerol (Sigma-Aldrich)
RPMI: Roswell Park Memorial Institute media (Gibco)
SCF: Stem Cell Factor (Gibco)
SP34: StemPro-34 serum-free mediums (R&D Systems)
TPO: Thrombopoietin (R&D Systems)
VEGF: Vascular Endothelial Growth Factor (R&D Systems)
SFD: Serum-free differentiation medium (5% IMDM, 1% B-27, 0.5% N-2 supplements
(Invitrogen), 1 mM (1%) L-glutamine, 0.5% BSA, and 22% Hams F12 medium
(Corning).)

69

Table 3.2. Summary of commercial antibodies used in this paper including their
indicated usage.
Catalog
Target
Source
Reactivity
Label
Company
Usage
Number
Monoclonal
BD
Flow
CD42b
Human
APC
551061
Mouse
Biosciences
Cytometry
Monoclonal
BD
Flow
CD42b
Human
PE
555473
Mouse
Biosciences
Cytometry
Monoclonal
BD
Flow
CD41a
Human
APC
559777
Mouse
Biosciences
Cytometry
Monoclonal
BD
Flow
CD41a
Human
PE
555467
Mouse
Biosciences
Cytometry
Monoclonal
BD
Flow
CD42a
Human
PerCP
340537
Mouse
Biosciences
Cytometry
Monoclonal
BD
Flow
CD42a
Human
PE
558819
Mouse
Biosciences
Cytometry
Annexin
BD
Flow
Bacteria
Human
FITC
556420
V
Biosciences
Cytometry
Monoclonal
BD
Flow
PAC-1
Human
FITC
340507
Mouse
Biosciences
Cytometry
BrdU
Monoclonal
Alexa
Flow
Human
Invitrogen
A23210
[PBR-1]
Mouse
Fluor 488
Cytometry
Polyclonal
Alexa
IgG
Human
Thermo
A-11013
IFM
Goat
Fluor 488
Monoclonal
MA5vWF
Human
N/A
Thermo
IFM
Mouse
14029
Mouse
Alexa
Donkey
Mouse
Thermo
A-21203
IFM
IgG
Fluor 594
PE: Phycoerythrin
APC: Allophycocyanin
FITC: Fluorescein isothiocyanate
IFM: Immunofluorescence microscopy
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Figures

HIV cpPu
5’ LTR PSI RPE

MiniCMV
TetO

WPRE

Oct4 F2A

Klf4

IRES

Sox2 E2A cMyc

dU3
3’ LTR

STEMCCA
Figure 3.1 Lentiviral vector schematic of inducible pHAGE-STEMCCA (adapted
from Sommer et al., Stem Cells. 2009178).
iPSCs were generated using a lentiviral vector that contained the 4 reprograming
transcription factors: Oct-4, Klf4, Sox2, and cMyc. Illustration indicates the single
multicistronic mRNA cassette. Expression of the 4 genes is under the control
doxycycline inducible promoter, TetO-miniCMV. cpPu: central polypuryne tract. dU3:
deleted U3. HIV: human immunodeficiency virus. IRES: internal ribosome entry site.
LTR: long terminal repeat. miniCMV: mini-cytomegalovirus. PSI: packaging signal. RRE:
rev responsive element. STEMCCA: stem cell cassette. WPRE: woodchuck hepatitis
virus post-transcriptional regulatory element.
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Ectoderm

Endoderm
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SSEA3
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Tra-1-60
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Figure 3.2 Confirmation of WT iPSC (WTBM1-8) pluripotent state.
(A) Karyotype of the WT iPSC line showing a normal human chromosomal pattern 23
chromosomal pairs and no abnormalities. (B) Teratoma formation and germ layer
analysis indicate the presence all three germ layers. (C) Flow cytometry of early ES cell
proteins and pluripotency markers in WT iPSCs using SSEA3, SSEA4, Tra-1-60, and
Tra-1-81179. WT iPSC line exhibited high levels of each marker after reprograming as
desired. SSEA: Stage-specific embryonic antigen. TRA: Tumor-related antigen.
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A

B

Figure 3.3 iPSC morphology.
(A) iPSCs on feeder layer on brightfield imaging. (B) Same as in (A), but iPSCs in
feeder-free culture. Images show representative iPSC colonies that were used for
culture and differentiation. White arrows indicate iPSC colonies and black arrows
indicate irradiated mouse embryonic fibroblast feeder layer. Brightfield images taken at
4X using Zeiss, Axio, Observer z.1 microscope.
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Mlu I-231
CAG enhancer
Kas I-1018
HIV-1_psi_pack
Not I-1524
CMV promoter
HIV-1 5'LTR
pBR322_origin
BstZ17 I-11646
RRE
SanD I-2310
lac_promoter
Fse I-11283
Pac I-2594
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cPPT
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Bleomycin
Avr II-10883
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SV40_Promoter
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Figure 3.4 Lentiviral schematic used for pFVIII expression
FVIII-containing viruses were made using the above lentiviral plasmid that contained F8
cDNA and mouse Cxcl4 (PF4) promoter. HPCs were transduced with lentivirus that
carried a transgene for one of three F8 cDNA variants: hBDFVIII, hBDFVIIRH and
hBDFVIIIΔ. Expression of FVIII was controlled and specific to Mks and platelets through
the use the Cxcl4 proximal promoter. Illustration shows the components of the viral
vector. The hBF8 constructs was made by Dr. Teeshell Greene based on the plasmid
pFUGW152, inserting the murine Cxcl4 promoter and human WT B-dmainless F8 cDNA
replacing the eGFP cDNA in pFUGW. pFPF8W was then modified by Dr. Guohua Zhao
in our group to remove second Xho I site and insert an Nhe I site in same position and
an Age I site at position 8363 after the F8 cDNA to facilitate insertion of hBDFVIIIRH and
hBDFVIIIΔ.
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Figure 3.5 FVIII lentivirus production.
Lentiviral vectors were made using a three-vector system184. 293T cells were cotransfected using PEI with vectors: F8 cDNA vector (Figure 3.5), psPAX2 viral packing
vector, and pMD26 viral envelop vector. 48-hours post infection, viral vectors were
collected from the supernatant and concentrated through ultracentrifugation as
described109,152.
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Figure 3.6 Schematic of experimental design using iMks to study pFVIII biology.
Peripheral blood mononuclear cells from patients were reprogrammed into iPSCs as
previously described178,179. IPSCs were differentiated into HPCs. HPCs were transfected
with a SIN lentiviruses expressing pFVIII or controls, and the HPCs were then
differentiated into iMks. After differentiation and maturation of pFVIII-iMks, these cells
were used for studies of pFVIII biology in vitro and in vivo.
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Figure 3.7 FVIII expression in iMks.
(A) DNA from 106 iMks was collected and analyzed for lentiviral integration. Viral
genomes per cell were expressed relative to non-transduced control (NTC, dashed line).
Mean ± 1 SEM are shown with the number of independent experiments indicated in each
bar. No difference was noted by ANOVA analysis between the lines. (B) 500 ng of total
RNA was analyzed for F8 message. NTC and eGFP-expressing iMks were used as
negative controls. Mean ± 1 SEM are shown with number of independent experiments
indicated in each bar. P values determined by one-way ANOVA. (C) 2x106 iMks were
lysed to extract cellular content. Whole cell lysates were analyzed using human FVIII
ELISA. Mean ± 1 SEM are shown with number of independent experiments indicated in
each bar. P values determined by one-way ANOVA. BD = hBDFVIII-iMks, RH =
hBDFVIIIRH-Mks, Δ = hBDFVIIIΔ-iMks, and h38 = Line h38 mouse platelets.
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Figure 3.8 Apoptotic effects of FVIII on iMks.
(A) TUNEL-stained for BrdU and co-stained for CD42b to examine for pFVIII-iMks
apoptosis. Mean ± 1 SEM are shown with number of independent experiments indicated
in each bar. No difference was noted by ANOVA analysis between the examined iMk
lines. (B) Annexin V binding as an indicator of apoptosis of iMks. Mean ± 1 SEM are
shown with number of independent experiments indicated in each bar. No difference
was noted by ANOVA analysis between the examined iMk lines.
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Figure 3.9 pFVIII effects on iMks.
(A) Agonist responsiveness of iMks to 1 unit of thrombin/ml and measuring FITC-labeled
PAC-1 antibody binding. For each iMk, the left bar is pre-thrombin and the right is postthrombin activation. Mean ± 1 SEM are shown with number of independent experiments
for each iMk condition is shown. P<0.001 for pre- versus post-thrombin activation for
each iMk condition by one-way ANOVA, but no difference was noted by ANOVA
analysis between the examined iMk lines. (B) Studies of iMk injury with loss of CD42b+
signal within the CD41+ as an indication of metalloproteinase cleavage of the
extracellular glycocalicin domain of the GPIbα chain182 are shown. Mean ± 1 SEM are
shown with number of independent experiments indicated in each bar. No difference
was noted by ANOVA analysis between the examined iMk lines.
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CXCL4 (A) and ITGA2B (B). In both (A) and (B), 500 ng of total RNA was analyzed for
message as described186. NTC and eGFP-expressing iMks were used as negative
controls. Mean ± 1 SEM are shown with number of independent experiments indicated in
each bar. Values calculated against TBP standard. (A) CXCL4 and (B) ITGA2B genes
showed

no

difference

in

80

comparison

to

controls.

A

WT

60

B

40

60

WT
RH

40

BD

C

WT

60
40

RH

RH

0

5

-20

10

15
20
Time (min)

25

BD

20

0
0

5

10

-20

20
15
Time (min)

25

NTC
Null
30

mm

0

NTC
BD
Null
30

20
mm

mm

20

0
0

-20

-40

-40

-40

-60

-60

-60

5

10

15
20
Time (min)

25

Figure 3.11 In vitro efficacy of pFVIII-iMks in ROTEM studies.
ROTEM studies as in Figure 2.3, but with added iMks instead of Line h38 platelets. BD =
BDFVIII-iMks added; RH = BDFVIIIRH-iMks added; and NTC = non-transfected control
iMks added. Each curve represents 5 independent studies. (A) Addition of 5X103 iMks to
110 µl of whole blood from FVIIInull mice. WT mice blood and FVIIInull (KO) mice blood
were studied as positive and negative controls, respectively. (B) Same as in (A) with
5X104 BD or RH iMks. (C) Same as in (A), but with (dotted lines) or without (solid lines)
10 nM rFVIIa also added to the samples. Arrows indicate the paired studies without and
with rFVIIa.
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Figure 3.12 pFVIII-iMk infusion efficacy in FVIIInull mice using the FeCl3-carotid
artery injury model.
5-10X106 iMks were infused into clodronate liposome-treated FVIIInull mice. (A) Human
platelets released from infused iMks were analyzed up to 24-hours post iMks infusion via
flow cytometry. Mean ± 1 SEM are shown with 5 independent studies. (B) Similar FeCl3carotid artery injury studies as in Figure 2.7 with the primary endpoint being remaining
blood flow as measured by AUC. Mean ± 1 SEM are shown with the number of
independent studies noted in the bar graphs. P values were done by one-way ANOVA.
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Chapter 4 – Megakaryocyte IgG uptake and AAVS1 FVIII targeting of iMks
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Abstract
Megakaryocytes and platelets take up specific proteins from blood circulation and store
them in their α-granules. This uptake includes a general uptake and storage of IgG. This
uptake should include neutralizing inhibitors of FVIII, which are virtually all IgGs. This
would imply that inhibitors are localized into the same granules as FVIII and should
either neutralize the pFVIII within the granules or neutralize FVIII after release if the IgG
and FVIII are stored in distinct α-granules. However, pFVIII remains effective upon
release at sites of vascular injury. Whether IgG taken up by Mks is stored in different
granules than FVIII has yet to be explored. This chapter outlines preliminary studies to
localize human IgG taken up by Mks using fluorescence microscopy, and indicates that
IgG does not localize with endogenous Mk vWF. Additionally, in this chapter, an
alternative approach to express pFVIII in iMks is explored through FVIII AAVS-1
correction of hemophilia A iPSCs. These studies seek to enhance pFVIII expression in
iMks as well as note some of limitations of using iMks.
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Introduction
Human FVIII inhibitors storage in α-granules
Mks and platelets store endogenously made proteins and small molecules within
three distinct granules: α, δ, and λ. α-granules contain proteins both made in the Mk or
taken up in circulation. α-granules contain proteins such as vWF, PF4, other
chemokines, and many more187. They also take up FV (in humans), albumin, fibrinogen,
and IgGs from their surroundings188,189. The exact method of uptake is an area of ongoing study, but it is thought to be receptor-mediated and clatharin-dependent189,190. To
date, the exact receptor that is responsible for uptake of plasma proteins has yet to be
identified.
It is hypothesized that once these proteins are taken up from circulation and
then are stored within the α-granules. After the development of our Line h38 transgenic
mice in 2003, our group showed that pFVIII was present in granules that overlapped with
granules that contained vWF, suggesting that pFVIII is largely stored in α-granules and
released upon platelet activation108,152. In the absence of vWF, our group has shown that
pFVIIII is still found at ~70% of the level in vWF-sufficient Mks, is still stored in αgranules and is functional when released191.
For pFVIII to be effective in the presence of high-titer inhibitors, it must be
shielded from circulating inhibitors. Given this information and the fact that IgG is
endocytosed and stored in α-granules, one would assume that inhibitors taken up by
Mks and platelets would be stored with pFVIII. If this is true, why isn’t the FVIII contained
within granules with inhibitors inhibited and rendered ineffective? And if IgG is stored at
high quantities and released upon platelet activation, why does the locally released IgG
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not inactivate released pFVIII? We hypothesize that IgG taken up by platelets is stored
in “uptake” α-granules that do not contain FVIII and that vWF and pFVIII are stored in
“endogenous” α-granules. Others have suggested the stored vWF protects the pFVIII
from inhibitors both in the granules and after subsequent release of both pFVIII/vWF.
They confirmed our findings that pFVIII is still stored at ~70% levels in type 3 vWD mice
and is functional in a FVIIInull setting. In addition, they also present tail-clip
exsanguination data that in Type 3 vWD/FVIIInull mice where pFVIII loses efficacy in the
presence of inhibitors. However, these results are limited to just one hemostatic
model192.

AAVS-1 correction
Previous studies by our group had utilized AAVS-1-targeting to express, under a
Gplba promoter, genes within differentiating iMks102. Our first attempt at AAVS-1
correction was by Spencer Sullivan. His report, in 2014, showed that he could correct
the defect in Glanzmann thrombasthenia due to defective αIIb in iMks and iPlts by
targeting ITGA2B-expression vector to the AAVS-1 locus. These studies demonstrated
that he could express aIIb at a high level via this insertion technology and the construct
utilized. Subsequently, Karen Vo using the same vector backbone and strategy, showed
she could overexpress FLI1 by ~5-fold in iMks, clearly at a lower level than that achieved
for αIIb, but still significantly higher than endogenous FLI1101.
The first part of this chapter outlines preliminary studies on the localization of
human IgG in Mks after endocytosis in vitro. Purified human IgG was added to Mk media
to allow for uptake into Mks. Localization was compared to vWF an endogenous αgranular protein and one of importance to pFVIII biology. This chapter also details
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AAVS-1 targeting of FVIII into WT iPSCs, results and implications to using this system to
express pFVIII.

Materials and Methods
Mk differentiation
iMks were differentiated as previously described in Chapter 3. Mouse Mks were
cultured and differentiated from bone marrow as previously described82,151.

Isolation of human IgG
Human IgG was isolated from healthy donors according to the Thermo Scientific
protocol (20399). All buffers and resins were equilibrated at room temperature prior to
the start of purification. 2 ml of Protein G agarose was packed into a support column
(Thermo). Then 5 ml of Binding buffer (PBS) was added to resin and column and
allowed to drain. Human plasma was isolated by spinning down whole blood for 10
minutes at 3000 RPM. Binding buffer and human plasma was mixed at 1:1 (V:V) and
then added to the column. After the column drained, 15 mls of Binding buffer was added
to wash the resin followed by 5 ml of Elution buffer (0.1M Glycine, pH 2.5). The elute
was collected in 0.5 ml fractions. The pH of each fraction was adjusted using 100 µl
Neutralization buffer (1M Tris-HCl pH 8.0). The protein concentration of each fraction
was determined using nano-drop, ND-1000 (NanoDrop) and bicinchoninic acid (BCA)
protein assay (Thermo Scientific).

Incubation of human IgG with Mks
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Human IgG was added to Mk culture and incubated for 16 hours at various
concentrations (0.001 - 1 mg/ml) at 37°C with D10 mouse Mks or D5 iMks. Mks were
washed the next day for intracellular IgG staining.

Intracellular staining and immunofluorescence microscopy
Washed Mks were fixed in 2% paraformaldehyde (PFA) solution for 2 minutes.
Fixed cells were then seeded onto slides using cytospin protocol. 100 µl of cell mixture
was loaded into specimen chamber (Cyto-Tek) with filter paper (Cyto-Tek). Cells were
spun for 1 minute to allow adherence. A circle was drawn around adherent cells using a
liquid blocker PAP pen (Sigma). vWF antibody (Table 3.1) was added into an Antibody
solution (PBS, 0.1% (W:V) BSA, 0.2% sapponin, 0.02% (W:V) NaN3) at a 1:100 dilution
(V:V) and allowed to incubate with the seeded cells for 1 hour at room temperature.
Slides were washed 3 times with Antibody solution and then 1:300 anti-mouse IgG and
1:400 anti-human IgG (see Table 3.1) were added to the Antibody solution and allowed
to incubate for 1 hour at room temperature. 4',6-diamidino-2-phenylindole (DAPI)
solution was then added at a concentration of 1:1000 (V:V) in antibody solution and then
incubate with seeded cells for 10 minutes. Cells were washed 3 times. A drop of
Mounting media (Thermo) was added to cells and then a coverslip placed and sealed
using clear nail polish on top of the slide. Images of Mks were taken using a DMi8 Leica
Microscope. Images were taken at 40X objective and captured via Hamamatsu
Photonics ORCA-Flash 4.0 sCMOS digital camera. Final images were processed using
imageJ64.

AAVS1 targeting of FVIII
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WT iPSCs were targeted through co-transfection of AAVS-1 targeting plasmid
and the right and left zinc finger nuclease vectors (Figure 4.3)102,193. Verification of
correct full plasmid sequences were confirmed by sequencing. Transfected cells were
grown on drug-resistant MEFs as previously described

102

. Cells containing the AAVS1

F8-expression construct were selected using 1.2µm/ml puromycin added to iPSC media
(Figure 4.3)102. Subsequent colonies were picked and analyzed for gene insertion.
Hemizygous or homozygous insertion of F8 cDNA was confirmed via southern blot as
previously described 102,178,179.

F8 mRNA and FVIII antigen
F8 mRNA and FVIII antigen levels in Mks were investigated as previously
described in Chapter 3.

Results
Localization of human IgG
After incubation with IgG, Mks were visualized via confocal laser scanning
immunofluorescence microscopy194. iMks showed that ~ 65% of IgG-positive granules
were not positive for vWF (Figure 4.1D), Mks not incubated with igG show no
background staining of IgG (Figure 4.1F). Incubation of human IgG with mouse Mks
indicate similar results (Figure 4.2).

AAVS-1 correction of iPSCs
iPSCs that had the Gplbα-promoted driven F8 cDNA targeted to AAVS-1 locus
and then differentiated into iMks show FVIII mRNA above NTC (Figure 4.4A).
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hBDFVIIIRH showed higher mRNA levels than hBDFVIII. CXCL4 mRNA showed no
difference among the groups (Figure 4.4B). Despite detectable F8 mRNA, both hBDFVIII
and hBDFVIIIRH antigen were not detectable by FVIII ELISA (Figure 4.4C).

Discussion

FVIII inhibitors
Isolated human IgG showed uptake into human and mouse Mks after 16-hour
incubation. These studies showed that this igG was largely located in granules that were
not associated with vWF (Figure 4.1C and 4.1G). While very preliminary, these data
suggest that the majority of IgG was located in granules that were not associated with
vWF, however a third of IgG was located in α-granules that did contain vWF, suggesting
that the “uptake” and endogenous α-granules may ultimately overlap. These studies do
not yet show that the uptake IgG overlaps with pFVIII containing granules, which we
previously shown only partially overlaps with vWF-containing granules108. Our attempts
to co-stain Mks for pFVIII were stymied due to low level of pFVIII expression in AAVS-1
targeted iMks. In addition effects have been made to try and tag endogenous FVIII either
with Human influenza hemagglutinin (HA) or eGFP.
In addition to being stored in separate granules to avoid intra-granular
neutralization of the pFVIII, we had postulated that the “uptake” and “endogenous” α granules might be differentially released. This differential release would prevent the
presence of neutralizing FVIII antibodies at the site of pFVIII release, perhaps initially.
Previous studies have shown that ~90% of all stored IgG in platelets is released upon
platelet activation195. How then is pFVIII still effective in these settings? The difference in
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distribution of released IgG from platelets and pFVIII may not occur on a global scale,
but on a micro-scale within a growing thrombus. Perhaps, microenvironments within a
growing thrombus release pFVIII from distinct granules in sufficient amounts relative to
the inhibitors to feed-forward the clotting cascade before being neutralized by inhibitors.
Detailed thrombus studies, perhaps with the cremaster laser injury model, may support
this hypothesis. To define the role of platelet vWF in the protective process, we can
repeat the in vitro and in vivo iMk studies in Chapter 3 using an iPSC line in which the
VWF gene is disrupted using CRISPR/Cas9 technology.

AAVS-1 FVIII expression
The lentiviral approach used in Chapter 3 requires re-infection of cells using the
appropriate expression vector with each differentiation and does not optimally take
advantage of iPSC technology. Establishing a specific sub-line from the parental iPSC
line WTBM1-8 that consistently expresses high levels of pFVIII without iMk injury would
be ideal. We therefore tried this approach using an AAVS1 strategy with pFVIII
expression driven with a strong Mk-specific promoter (Gp1ba), which allowed the level of
ITGA2B mRNA expression to reach >50% of the level seen for the native ITGA2B
gene102, which is one of the highest expressed gene in developing megakaryocytes80.
We did achieve D6 iMks that expressed F8 mRNA at up to 4 times the amount as their
non-transfected control (Figure 4.4A) however; this was not sufficient to produce
detectable levels of FVIII antigen within iMks above WT background (Figure 4.4C). Our
data with the lentiviral approach in Chapter 3 suggest that the FVIII mRNA levels
obtained by AAVS-1 targeting is 10-fold too low an expression level to see comparable
FVIII levels described there and even that may still be an order of magnitude less than
desired as seen in Line h38.
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Sequence analysis of the resulting AAVS1 vector did not provide an explanation
of why this particular construct as opposed to the ITGA2B cDNA construct and the FLI1
cDNA construct was unsuccessful. Additional targeted clones were chosen, cultured,
and analyzed for FVIII expression to rule out potential sub-clone bias. Futhermore, this
particular Gplba -promoter driven construct may not be successful and if we shuttled the
Cxcl4-promoter driven F8 cDNA from the lentiviral constructs, perhaps we would have
achieved greater levels and success.
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Figure 4.1 Localization of human IgG in iMks post incubation.
(A-D) Immunofluorescence microcopy of iMks incubated with isolated human igG for 16
hrs. Magnification at 40X. (E-F) Immunofluorescence microcopy of control iMks not
incubated with human IgG. (A) DAPI (B) human IgG (C) vWF (D) Merged image. IgG.
(E) DAPI (F) human IgG (G) vWF (H) Merged image. Red arrows indicate vWF, green
arrows indicate human IgG.
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Figure 4.2 Mouse Mks incubated with human IgG.
(A-C) Immunofluorescence microcopy of mouse Mks incubated with isolated human IgG
for 16 hours. Magnification at 40X. (A) vWF (B) human IgG (C) Merged image. All
images show representative of experiments. Red arrows indicate vWF and green arrows
indicate human IgG.
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Figure 4.3 Vector Schematic of the AAVS1 targeting ZFN, targeting plasmid,
AAVS-1 locus for FVIII expression (Adopted from Hockemeyer et al.102,193)

Components for AAVS1 targeting of F8 to iPSCs. (A) Vector schematic of PGK-ZFN-L
and PGK-ZFN-R plasmids that contain components to target ZFNs to the HA of the
AAVS1 locus. Expression of ZFNs are controlled by the PGK promoter(B). AAS1 locus
and AAVS1 targeting plasmid containing F8 gene. Plasmid indicates HAs that over lab
with HAs of ZFNs to apply for insertion of F8 into the AAVS1 locus. Plasmid also
contains puromycin resistance and Gplbα promoter to express F8 in Mks and platelets.
(C) Schematic shows proper insertion of F8 into AAVS1 locus.
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Figure 4.4 FVIII expression in WT iMks after AAVS-1 targeting.
N=5

(A) and (B) 500 ng of total RNA isolated from D6 iMks was analyzed for F8 and CXCL4
(PF4) message using qRT-PCR. NTC was used as a negative control. Mean ± 1 SEM
are shown. N=6 for all studies. (C) 2x106 iMks were lysed to extract cellular content.
Whole cell lysates were analyzed using human FVIII ELISA. Mean ± 1 SEM are shown.
N=6 studies per arm.
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Chapter 5 – Discussion and Future Directions
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Discussion

These studies sought to address the limitations of pFVIII gene therapy by BMT
and offer an alternative route of pFVIII delivery that is not permanent. In these studies,
we have tested the concept of whether infusions of platelets that can deliver pFVIII could
be a potential strategy for treating patients with severe hemophilia A and intractable
inhibitors using Line h38 platelet infusions. We provide proof-of-principle both in in vitro
and in vivo hemostatic models that human pFVIII-expressing murine platelets can
improve hemostasis. The pFVIII hemostatic effect lasted several days even in mice
where platelet half-life is approximately half of that in humans. This hemostatic effect
was additive in the presence of rFVIIa and effective in the presence of inhibitors. To
further these studies and show that infused Mks can also deliver this same therapy and
that it is applicable to human Mks, we utilized iPSC-derived Mks that expressed FVIII.
This approach allowed us to have a renewable resource of cells that we could gene
manipulate in vitro and expanded to limitless amounts. Studies with pFVIII-iMks support
Line h38 studies and suggest that once robust technologies are developed to generate
clinically relevant platelets – be it from iPSCs or from another cell line such as adipose
cells116,117 – such technology could have application beyond just providing an alternative
source of platelet transfusions, but serve as a delivery system for various therapeutic
agents, perhaps beginning with pFVIII in the described clinical setting.

Implications for future studies
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Infusion of Line h38 platelets
Our studies seek to extend previous research done in the field of pFVIII, which
was always envisioned to lead to BMT-based therapies. Thus while others had shown
that pFVIII-containing platelets can improve hemostasis in a ROTEM model, FeCl3
carotid artery injury, and tail-clip exsanguination assays, none of those studies were
focused on using these for proof-of-principle of using infused pFVIII platelets as a
therapy. Thus no study defined how long the hemostatic effects last, the additive effects
with rFVIIa and its application in the presence of inhibitors.
On the other hand, our studies with Line h38 are also limited. While we show that
infusions of 15% Line h38 platelets is sufficient to correct the bleeding phenotype seen
FVIIInull mice in the presence and absence of inhibitor, our studies were limited by the
relatively low levels of pFVIII in Line h38 platelets which have the whole blood
equivalency of 3% FVIII plasma activity (as human FVIII has ~30% activity within murine
plasma107,108). Thus in our studies with ≤15% Line h38 platelets, the blood would have
the equivalency of ≤0.6%FVIII activity. This low level of FVIII may contribute to the suboptimal contraction seen on ROTEM studies (Figure 2.4). In the tail-clip exsanguination
assay, the efficacy of pFVIII at such low levels is consistent with our prior proposal that
the tail-clip exsanguination assay is especially sensitive to pFVIII. Calculated levels of
plasma equivalent FVIII activity 72 hours after Line h38 platelet infusion would have
levels as low as 0.02% and this was still effective in this hemostatic challenge (Figure
2.6). Finally, the low pFVIII levels may explain why a high concentration of sclerosing
FeCl3 was needed in the carotid artery studies with the endpoint of decreased arterial
blood flow rather than full occlusion (Figure 2.7). Thus, if only low levels of pFVIII can be
achieved in patients, its clinical value may be too limited especially in the presence of
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high-titer inhibitors. Whether that low level would still be beneficial and useful in
conjunction with rFVIIa would then need to be addressed. Thus clearly achieving at least
the higher level seen in a recent transgenic mouse report may be of value123.

pFVIII-iMks
In vitro-grown human Mks from various sources have been used to generate
platelets both by direct harvesting of so-called platelet-like particles (PLPs) in culture or
by using various bioreactors196-198. Many of these PLPs lack surface CD41 and are not
even derived from Mks199,200. Moreover of the CD41+-PLPs, only a small percent are
non-injured annexin V negative/CD42b+ platelets. Not surprisingly, these PLPs have
limited half-life in circulation post-infusion, are pre-activated, and have poor agonist
responsiveness199,201. On the other hand, PLPs released from intravenous infusion of
human Mks shed within the lungs over the subsequent few hours may be functional
platelets as it has been recently shown that endogenous marrow Mks travel to the lungs
where they account for ~50% of normal platelet release of platelets in mice71. We
previously shown that such released platelets from infused human Mks have a
Gaussian-size distribution, circulating half-life and agonist responsiveness similar to
well-prepared, fresh, donor-derived platelets151.
Remarkably, even with the low level of pFVIII in the studied iMks, the low number
of platelets released per iMk and shortened released human platelet half-life, efficacy in
the FeCl3-carotid artery injury model was seen, especially with the RH variant (Figure
3.12). This better improvement with RH compared to BD pFVIII was also seen in the
ROTEM studies (Figure 3.11). While RH antigen levels were higher than the BD pFVIII
in iMks, this difference was small (Figure 3.7), and not likely solely responsible for the
greater efficacy of RH. Moreover, this finding is also consistent with our previous studies
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showing that FVIIInull mice expressing RH after lentiviral gene therapy had greater
efficacy in improving hemostasis in the cremaster arteriole laser injury model due to
increased RH stability within the core of the growing thrombus109.
Our pFVIII-iMks studies also have several important limitations. iMks are known
to be small with low ploidy and release ~10 platelets/iMk even upon infusion into
recipient mice. At present, there was no available FVIIInull murine model on an immune
compromised background that was available for infusion studies, so we infused iMks into
clodronate liposome-treated FVIIInull mice to improve human platelet half-life by reducing
phagocytic removal of the human platelets. To test the full potential of this model, a
mouse would need to be developed to allow for long-term circulation of iMks and their
released platelets. The survival of the released human platelets in clodronate liposomepretreated FVIIInull mice (Figure 3.12A) was shorter than the ~12 hours seen when
human iMks were infused into immunodeficient mice. Currently we are breeding Nonobese (NOD)/SCID/interferon receptor 2γ-deficient (NSG)-FVIIInull mice obtained from
Dr. Shu-Wha Lin at Taiwan University. We plan to cross these mice with a mouse that
have a mutation in their Vwf gene (vWFR1326H) that allows for better incorporation of
human platelets into mouse thrombi as described by Tom Diacovo202. This will allow us
to fully test the therapeutic benefit of pFVIII-iMks over longer periods of time and in the
presence of inhibitors. These mice will also allow us to test other models of thrombosis.
To date, because of the low integration of human platelets into mouse thrombi, we were
precluded from using cremaster laser injury models for these studies. These new mice
will allow us to perform these studies and further test the details of the hemostatic
efficacy of our pFVIII-iMks
Additionally, in these studies we failed to show iMks’ effectiveness in the setting
of infused inhibitors. Whether pFVIII-iMks will be beneficial in the FeCl3 or tail-clip
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exsanguination model has yet to be fully elucidated; however, current studies to this end
are underway. More importantly, the level of pFVIII in these iMks was even lower than
that of the Line h38 platelets, and clearly a strategy to achieve higher levels of pFVIII per
iMk needs to be established as well as to establish a self-replicating lineage. Chapter 4
outlines other strategies utilized to express FVIII into iMks. So far our lentiviral approach
gave the highest amounts of antigen. In subsequent studies, we also hope to utilize FVIII
variants that have increased expression and/or biological activity in addition to the ones
outlined in this thesis.

IgG localization
While our main goal was for the use of infused pFVIII-iMks as an effective
hemostatic strategy in patients with high titer inhibitors, we also wanted to better
understand why pFVIII was more effective than plasma FVIII in the care of patients with
hemophilia A and inhibitors. In both plasma and pFVIII, FVIII is bound to vWF, so we felt
that there should be an alternative explanation other than vWF binding to explain the
difference efficacy in the setting of inhibitors. We hypothesized that the pFVIII was either
localized in different granules than endocytosed IgG in absolute terms or in sufficient
amounts to allow efficacy or that there were macro- or micro-domains within the
interstices of a thrombus that contained free pFVIII able to activate the clotting cascade
sufficiently before being neutralized. We began with confocal microscopy to test this
hypothesis. Human IgG granular distribution only partially overlapped with that of vWF.
Further studies would need to be done to test this hypothesis by looking at colocalization of pFVIII in iMks, where pFVIII expression level is increased, and colocalization with endogenously expressed vWF and endocytosed human IgG. Also iMks
that have targeted disruption of vWF will need to be studied and perhaps the ability of
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these two iMk populations to release platelets in FVIIInull mice will need to be looked on
in situ microscopy. The former hypothesis is supported in a 2011 study by Kamykowski
et al. This group showed that proteins with pro and anti-agonist functions stored within
platelets showed very little co-localization within the same α-granules when visualized
via confocal microcopy203. Understanding the basis for enhanced pFVIII resistance to
inhibitors may provide insights that can lead to new strategies to improve this biology for
example by enhancing vWF levels in pFVIII-iMks.

Strategies to increase pFVIII expression within iMks
In our studies, we utilized HPCs transduced with the appropriate lentiviruses to
obtain pFVIII-iMks. These experiments were limited by the amount of virus we could add
to the cells without having adverse effects due to viral toxicity. One approach that can be
taken to not need to constantly transfect cells with lentiviruses is to accomplish the
genetic modification at an earlier self-replicative stage. We described such a strategy
using AAVS-1 targeting of vector constructs in iPSCs to drive megakaryocyte-specific
expression using a Gp1ba promoter, but while this strategy had achieved high levels of
eGFP expression and correction of αIIb expression in iMks, it did not drive significant
expression of pFVIII (Figure 4.4). While increased F8 mRNA was obtained due to AAVS1 targeting, this level of mRNA was at least 40-fold too low for achieving a useful pFVIIIiMk when compared to the pFVIII-iMks that were transduced with lentivirus.
Through lenti-viral targeting of FVIII in iMks we were able to achieve modest
levels of FVIII when compared to our Line h38 transgenic Mks (Figure 3.7). Interestingly,
to achieve this relatively low level of pFVIII, HPCs needed to transduced with 10 viral
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particles per cell that resulted in a FVIII mRNA level of at least 40 times greater than
controls
We also explored other strategies to express FVIII within iMks, not outlined in this
thesis. Of note, we tried to introduce hBFVIII plasmids through electroporation into HPCs
to increase F8 cDNA, mRNA, and antigen. We gave a dose of DNA that was well
tolerated by Meg-01 line cells however, this dose caused cell arrest in HPCs and no
production of FVIII. We also tried a 100-fold increase in lentiviral transduction which only
yielded a modest increase in iMk FVIII (data not shown). Clearly, we may have
challenges achieving this goal on two levels: 1.tolerance of the induction system and the
amount of DNA given that allows for the survival of the iPSCs or HPCs and 2.expression
levels of ectopic pFVIII and their ability to cause apoptosis of differentiating Mks.

Other limitations of the pFVIII-iMk infusion approach
One area of potential concern with pFVIII-iMks approach (beyond those that may
be associated with infusion of iMks in any clinical setting) is the need to infuse large
numbers of platelets into mice and potentially humans that are not thrombocytopenic.
Infusing high levels of platelets may induce untoward thrombosis causing symptoms
seen in thrombocytosis204. We tested whether a modest 15% increase in pFVIII could
have a beneficial effect on thrombosis and hemostasis. These studies did not address
the upper limits of infusing large amounts of platelets. While we did not indicate any
adverse effect in mice receiving 15% platelet infusions, further studies would need to be
completed to ensure that maximum benefit of pFVIII could be achieved without
thrombotic risks. We propose that a once weekly to every other week infusion of pFVIIIiMks would provide prophylactic therapy with no notable increase in platelet counts. This
may need to be tested in mice models after we establish the NSG-FVIIInull mice.
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Clinical application
For pFVIII infusion therapy to reach clinical applications, the aforementioned
limitations would have to be addressed. Once these limitations are addressed, we
envision pFVIII therapy being beneficial in several areas of hemophilia A with severe
inhibitors. One scenario for pFVIII infusion therapy could be that a patient with
intractable inhibitors would receive products derived from “universal” pFVIII-iMks, which
would release platelets missing particular human leukocyte-related antigens (HLA) on
their surface205. This could be accomplished through reprogramming cells from healthy
individuals and gene manipulating iPSCs to lack HLA antigens. Our group is beginning
to work with Dr. David Russell at the University of Washington on this project206. This
would prevent the need to reprogram each patient’s cells and allow for better selection of
iPSC lines that not only give rise to the highest level of iMks, but lines that also express
FVIII the best.
Alternatively, patients may have their own iPSCs established and utilized to
generate pFVIII-iMks. Both strategies may avoid the development of antibodies to the
infused platelets and allow long-term treatment requiring transfusion every 1-2 weeks or
longer with limited increases in their total platelet counts. Applying this strategy to pFVIII
delivery would provide insights into what type of clinically relevant bleeds pFVIII therapy
would be useful for and whether, in a particular patient with specific inhibitors, there
would be benefit from a more permanent pFVIII therapy using marrow-directed gene
therapy. Furthermore, the pFVIII-iMks may then be useful to support such challenging
patients during their post-BMT thrombocytopenia with its anticipated increased bleeding
risks.
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Conclusion
In summary, we studied the potential of an alternative approach for using pFVIII
strategy to treat patients with severe hemophilia A and intractable inhibitors. Using
transgenic mouse Line h38 platelets and WT iPSCs modified to express FVIII when
differentiated into iMks, we show the utility of prophylactic infusions of pFVIII on
achieving several days of hemostasis in FVIIInull mice. This pFVIII strategy was also
effective in the presence and absence of inhibitors and was additive with a bypassing
agent, rFVIIa. iMks expressing both hBDFVIII, hBDFVIIIRH were able to effect clot
formation and thrombosis both in vivo and in vitro. hBDFVIIIRH had more of an effect in
these settings than hBDFVIII. I also looked at IgG uptake into Mks and found that it
largely localizes to granules that are not associated with vWF, which may further explain
the efficacy of pFVIII in the setting of inhibitors. Prophylactic infusions of pFVIII has the
advantage of not permanently altering the patients, can provide longer lasting
prophylaxis than present-day bypassing agents, and be used in conjunction with these
bypassing agents. This approach may also be a useful adjuvant for bleeding challenges
post-marrow transplantation for gene therapy. Finally, it may be a first-to-clinic
application of in vitro-generated megakaryocytes and their derived platelets that would
justify the costs of preparing such a platelet product relative to donor-derived platelets.
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